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ABSTRACT 
Antibiotic-resistant bacterial infections will remain an extremely serious 
health-security and economic threat for the United States—and the world—unless steps 
are taken to curb them. This thesis focuses on antibiotic use in agriculture and potential 
methods to slow resistance. By examining existing U.S. policies at the national and state 
level as well as policies in Denmark and the Netherlands, this research finds that the 
European countries have reduced antibiotic use and decreased resistant organisms present 
in food animals. This thesis recommends implementing a multifaceted policy package 
beginning with the creation of an enhanced, more integrated surveillance system, then 
enacting antibiotic-use reduction targets, prohibiting the use of antibiotics in healthy 
animals and requiring veterinarians to examine animals before prescribing them 
antibiotics for disease prevention. The United States must implement more policies that 
respond to this global threat to preserve medically important antibiotics that protect the 
health and safety of people and animals. The homeland security enterprise should 
prioritize antibiotic resistance as a threat and work collaboratively to implement 
strategies to mitigate it. 
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Antibiotic resistance is an emerging biological threat that poses an increasing risk 
to the United States and to the world.1 The Centers for Disease Control and Prevention 
estimates that two million people are infected with drug-resistant bacteria annually and 
23,000 deaths each year can be blamed on these infections.2 According to the World 
Health Organization, resistant illnesses across the world are becoming more numerous 
and extremely difficult, and in some cases impossible, to treat with antibiotics.3 Bacteria 
that cause illnesses such as pneumonia, salmonellosis, shigellosis, gonorrhea, and 
tuberculosis may soon be completely resistant to antibiotics, rendering these conditions 
untreatable.4 The increasing number of antibiotic-resistant bacterial infections will 
remain a serious health-security and economic threat for the United States—and the 
world—unless steps are taken to curb it. 
Many factors have contributed to the acceleration of the antibiotic resistance 
threat; however, the focus of this thesis is on the use of antibiotics in agriculture. While 
data regarding the use of antibiotics in food animals are limited, some sources report that 
80 percent of all antibiotics sold in the United States are used for livestock.5 There is 
consensus among researchers that antibiotic use in food animals may contribute to 
antibiotic resistance in humans; dozens of studies and trials suggest a causal 
relationship.6 Given the amount of antibiotics used in animal husbandry, there is a need 
                                                 
1 “Written Testimony of OHA for a Senate Committee on Homeland Security and Governmental 
Affairs Hearing Titled ‘The Federal Perspective on the State of Our Nation’s Biodefense,’” Department of 
Homeland Security (DHS), April 14, 2016, https://www.dhs.gov/news/2016/04/14/written-testimony-oha-
senate-committee-homeland-security-and-governmental-affairs. 
2 “Antibiotic/Antimicrobial Resistance,” Centers for Disease Control and Prevention, accessed August 
23, 2017, https://www.cdc.gov/drugresistance/index.html. 
3 World Health Organization, Antimicrobial Resistance: Global Report on Surveillance 2014 (Geneva, 
Switzerland: World Health Organization, 2014), XI. 
4 World Health Organization. 
5 Michael J. Martin, Sapna E. Thottathil, and Thomas B. Newman, “Antibiotics Overuse in Animal 
Agriculture: A Call to Action for Health Care Providers,” American Journal of Public Health 105, no. 12 
(December 2015): 2409–10, https://doi.org/10.2105/AJPH.2015.302870. 
6 Timothy F. Landers et al., “A Review of Antibiotic Use in Food Animals: Perspective, Policy, and 
Potential,” Public Health Reports 127, no. 1 (2012): 4–22. 
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to explore evidence-based agricultural practices that curb the threat of antibiotic 
resistance.  
This thesis examines current national and state-level agricultural strategies 
undertaken in the United States to slow the pace of antibiotic resistance and reviews 
policies and practices implemented abroad in Denmark and the Netherlands. These 
policies are grouped into the following categories for comparison:  
• Legislative bans: illegal nontherapeutic uses, prohibited drug classes or 
drug classes with limits for use in food animals, and comparisons of 
penalties for noncompliance with policies  
• Antimicrobial dispensing: requirements for veterinarians such as 
educational outreach, the level of oversight required by veterinarians, and 
limits on duration of treatment  
• Monitoring requirements: i.e., requirements to review and report antibiotic 
distribution and use data; resistance levels in food, animals, and people; 
and sectors required to report antibiotic use data  
• Outcomes and results: whether the policies implemented resulted in an 
overall reduction in antibiotic use and resistance in animals, and resistant 
infections in people 
Taken together, the studied European countries appear to be slowing the threat of 
antibiotic use as a result of their policies—policies that the United States has largely not 
implemented. These countries also have robust surveillance systems that allow 
stakeholders to monitor trends and change course if needed. The Netherlands, 
particularly, achieved an overall reduction in antibiotic use, as well as reductions in 
resistant organisms in food animals and resistant infections in people.  
This analysis leads to this thesis’s proposal of several potential strategies to slow 
the threat of antibiotic resistance in the United States: 1) creating an enhanced, more 
integrated surveillance system, 2) enacting antibiotic-use reduction targets, 3) prohibiting 
the use of antibiotics in healthy animals, and 4) requiring veterinarians to examine 
xix 
animals before prescribing them antibiotics for disease prevention. Each strategy is 
assessed using the Centers for Disease Control and Prevention’s policy analytical 
framework, which analyzes the impact or reach the policies may have, how feasible they 
are to implement, and the potential economic and budgetary impacts.  
This thesis recommends implementing all four policies as a package, but 
acknowledges that policymaking related to antibiotic resistance and agriculture in the 
United States has historically not been successful and has faced much opposition. 
Therefore, this thesis proposes implementing the policies in a phased approach beginning 
with increasing data collection and building an integrated surveillance system to promote 
informed decision-making regarding antibiotic resistance.  
Further research is needed to address areas outside the scope of this thesis, such as 
farmer and veterinarian knowledge and attitudes about antibiotic resistance, antimicrobial 
resistance related to companion animals, animal waste management and its effects on 
antibiotic resistance, organic farming, agriculture antimicrobial-stewardship technical 
assistance organizations, and European food production practices that could be adopted in 
the United States. 
Congress and governmental agencies must examine the successes of other nations 
that have actively responded to this global threat and work with industry partners to gain 
buy-in and acceptance of responsibility and duty to preserve medically important 
antibiotics to protect the health and safety of people and animals. The homeland security 
enterprise should prioritize antibiotic resistance as a threat and work collaboratively to 
implement the strategies outlined in this thesis to mitigate it. 
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I. ANTIBIOTIC RESISTANCE AS A HOMELAND SECURITY 
ISSUE 
Antibiotic resistance is an emerging biological threat that poses an increasing risk 
to the United States and to the world.1 The Centers for Disease Control and Prevention 
(CDC) estimates that two million people are infected with drug-resistant bacteria 
annually and 23,000 deaths each year can be blamed on these infections.2 According to 
the World Health Organization, resistant illnesses across the world are becoming more 
numerous and are extremely difficult, in some cases impossible, to treat with antibiotics.3 
Bacteria that cause illnesses such as pneumonia, salmonella, shigella, gonorrhea, and 
tuberculosis may soon be completely resistant to the antibiotics available today, rendering 
the conditions untreatable.4 The increasing number of antibiotic-resistant bacterial 
infections will remain a serious health-security and economic threat unless steps are taken 
to curb it. 
Many factors contribute to the acceleration of the antibiotic resistance threat; 
however, the focus of this thesis is the use of antibiotics in agriculture. While data 
regarding the use of antibiotics in food animals are limited, some sources report that 
80 percent of all antibiotics sold in the United States are used for livestock.5 The U.S. 
Food and Drug Administration (FDA) reports that, in 2015, more than 21 million pounds 
of all antimicrobial drugs considered medically important in human medicine were sold 
                                                 
1 “Written Testimony of OHA for a Senate Committee on Homeland Security and Governmental 
Affairs Hearing Titled ‘The Federal Perspective on the State of Our Nation’s Biodefense,’” DHS, April 14, 
2016, https://www.dhs.gov/news/2016/04/14/written-testimony-oha-senate-committee-homeland-security-
and-governmental-affairs. 
2 “Antibiotic/Antimicrobial Resistance,” Centers for Disease Control and Prevention (CDC), accessed 
August 23, 2017, https://www.cdc.gov/drugresistance/index.html. 
3 World Health Organization, Antimicrobial Resistance: Global Report on Surveillance 2014 (Geneva, 
Switzerland: World Health Organization, 2014), XI. 
4 World Health Organization. 
5 Michael J. Martin, Sapna E Thottathil, and Thomas B. Newman, “Antibiotics Overuse in Animal 
Agriculture: A Call to Action for Health Care Providers,” American Journal of Public Health 105, no. 12 
(December 2015): 2409–10, https://doi.org/10.2105/AJPH.2015.302870. 
2 
for use in food-producing animals—a 26-percent increase in sales from 2009.6 In fact, 97 
percent of these medically important drugs were sold over the counter, meaning they 
were available without a prescription or directive from a veterinarian.7 There is 
consensus among researchers that antibiotic use in food animals may contribute to 
antibiotic resistance in humans; dozens of studies and trials suggest a causal 
relationship.8 Given the large amount of antibiotics used in animal husbandry, there is a 
need to explore evidence-based agricultural practices that curb the threat of antibiotic 
resistance. 
Antibiotic resistance refers to a pathogen’s ability to continue growing or resist 
being killed by the drugs used to treat infections, through the process demonstrated in 
Figure 1. When a person takes an antibiotic for an infection, sometimes not all bacteria 
are killed. The resistant bacteria survive and will continue to multiply. Unfortunately, 
resistant bacteria can then spread to other people or animals.9 Patients with infections 
caused by drug-resistant bacteria consume more health-care resources than patients 
infected with strains of non-resistant pathogens and are at a higher risk of poor health 
outcomes or death.10  
                                                 
6 Food and Drug Administration (FDA), “2015 Summary Report on Antimicrobials Sold or 
Distributed for Use in Food-Producing Animals” (report, Department of Health and Human Services, 
2016), 52, https://www.fda.gov/downloads/ForIndustry/UserFees/AnimalDrugUserFeeActADUFA/ 
UCM534243.pdf. 
7 FDA, 54. 
8 Timothy F. Landers et al., “A Review of Antibiotic Use in Food Animals: Perspective, Policy, and 
Potential,” Public Health Reports 127, no. 1 (2012): 4–22. 
9 CDC, “Antibiotic/Antimicrobial Resistance.” 
10 Damien Roux et al., “Fitness Cost of Antibiotic Susceptibility during Bacterial Infection,” Science 
Translational Medicine 7, no. 297 (July 22, 2015), https://doi.org/10.1126/scitranslmed.aab1621; C. Lee 
Ventola, “The Antibiotic Resistance Crisis,” Pharmacy and Therapeutics 40, no. 4 (April 2015): 277–83; 




Figure 1. Process of Antibiotic Resistance11 
A. IMPORTANCE 
The CDC’s “Antibiotic Resistance Threats in the United States, 2013” includes an 
assessment and prioritization of bacteria based on their threat level. The report, which 
was created with the help of experts from a workgroup serving the CDC Office of 
Infectious Diseases Board of Scientific Counselors, claims an estimated 610 deaths 
annually from carbapenem-resistant Enterobacteriaceae (CRE), bacterial infections 
typically acquired in health-care settings; 11,000 deaths attributable to methicillin-
resistant Staphylococcus aureus (MRSA), which can be acquired in the community as 
well as in health-care settings; and 14,000 deaths annually from Clostridium difficile 
(C.difficile) infections, another health-care-associated infection.12 Also included in the 
estimates are multidrug-resistant tuberculosis, drug-resistant Salmonella, drug-resistant 
Campylobacter, and drug-resistant Neisseria gonorrhoeae. Public health professionals 
have been focusing on surveillance of these drug-resistant organisms for the last several 
decades.  
                                                 
11 Source: CDC, “Antibiotic Resistance Threats in the United States, 2013” (report, U.S. Department 
of Health and Human Services, 2013), https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. 
12 CDC, 15–16. 
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The CDC classifies three drug-resistant bacteria as “urgent threats”: Clostridium 
difficile, carbapenem-resistant Enterobacteriaceae (CRE), and Neisseria gonorrhoeae.13 
An “urgent” classification signifies a threat that may not be widespread yet, but could be. 
If an outbreak of any of these pathogens emerges, it would require significant and urgent 
public health response to perform surveillance and stop the spread. The CDC reports that 
“some CRE bacteria have become resistant to most available antibiotics”; of patients who 
are sick with blood stream infections due to CRE, nearly half do not survive.14 A more 
common bacteria is listed in the “serious threat” level—Streptococcus pneumoniae, 
which is responsible for meningitis and bacterial pneumonia. These bacteria cause 1.2 
million drug-resistant infections and kill 7,000 people each year.15 
B. ANTIBIOTIC RESISTANCE AND AGRICULTURE 
In many parts of the world, low doses of antibiotics and other antimicrobials are 
given to livestock to accelerate growth and prevent disease among animals living in close 
quarters in less-than-sanitary conditions. As Figure 1 showed, bacteria that survive low 
doses of antibiotics become resistant to drugs. When resistant organisms are prevalent on 
farms, it becomes a serious issue for the public’s health since many of the drugs provided 
to animals are also used in human medicine. The infographic in Figure 2 describes how 
antibiotic resistance in animals can impact people. 
                                                 
13 “Antibiotic/Antimicrobial Resistance, Biggest Threats,” CDC, February 27, 2018, 
https://www.cdc.gov/drugresistance/biggest_threats.html. 
14 “Carbapenem-Resistant Enterobacteriaceae in Healthcare Settings,” CDC, February 26, 2018, 
https://www.cdc.gov/hai/organisms/cre/index.html. 
15 CDC, “Antibiotic/Antimicrobial Resistance, Biggest Threats.” 
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Figure 2. How Antibiotic Resistance Spreads16 
There are two main ways that antibiotic-resistant bacteria develop—in the guts of 
animals and in the guts of humans. Antibiotic-resistant organisms can be transmitted in 
multiple ways. For example, drug-resistant bacteria can be present in animal meat; if the 
meat is not prepared properly, the resistant bacteria can spread to humans who consume 
the meat, where the resulting infections can be extremely difficult to treat. In fact, the 
CDC highlights several drug-resistant organisms in its aforementioned “Antibiotic 
Resistance Threats” report, three of which are foodborne organisms that are becoming 
drug-resistant: Campylobacter, Salmonella, and Shigella.17 To slow the emergence and 
                                                 
16 Source: CDC, “Antibiotic Resistant Threats in the United States.” 
17 CDC. 
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spread of antibiotic-resistant bacteria, we must be sensible about using antibiotics in 
humans and animals. The sections that follow describe the effects antibiotic resistance 
has on humans, the agriculture industry, and food security.  
1. Salmonella Heidelberg Outbreak 
According to the CDC, an estimated 1,200,000 Salmonella infections occur each 
year, costing $365 million in medical expenses.18 Of those infections, 100,000 are 
estimated to be resistant to antibiotics.19 In November 2016, the CDC worked with 
several states to investigate a multistate outbreak of multidrug-resistant Salmonella 
Heidelberg infections. The investigation identified dairy bull calves from Wisconsin as 
the likely source; an overwhelming majority of the patients interviewed, 63 percent, 
reported coming in contact with dairy calves or cattle.20 Some farmers also reported that 
their dairy bull calves became sick or died. Salmonella bacteria are commonly found in 
the intestines of cattle and can be passed to humans through direct contact with animal 
feces and their environment. Salmonella bacteria can also be transmitted from one person 
to another.21  
Fifty-six people from fifteen states were reported to be infected with the outbreak 
strain—more than one-third of them children under the age of five.22 Thirty percent of 
those sickened required hospitalization for their infections and fortunately no deaths were 
reported.23 CDC tests concluded that this organism was resistant to multiple types of 
antibiotics, which meant there were limited treatment options and further testing was 
                                                 
18 CDC. 
19 CDC. 
20 “Multistate Outbreak of Multidrug-Resistant Salmonella Heidelberg Infections Linked to Contact 
with Dairy Bull Calves,” CDC, February 16, 2018, https://www.cdc.gov/salmonella/heidelberg-11-
16/index.html. 
21 “Salmonella Heidelberg FAQ,” Wisconsin Department of Health Services, accessed December 3, 
2016, https://www.dhs.wisconsin.gov/salmonella/heidelberg/faq.htm. 
22 CDC, “Multistate Outbreak.” 
23 CDC. 
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needed for each individual’s infection to determine which antibiotic would be 
successful.24  
Fortunately, this outbreak was limited in scope and severity; however, this 
example illustrates how multidrug-resistant organisms found within agricultural settings 
can transform into human infections and can cause a dangerous treatment situation for 
those who become ill.  
2. Agricultural Impact and Food Security 
Livestock is an important food source and a major contributor to the world 
economy. While antibiotics play a critical role in disease treatment in food animals, 
misuse of antibiotics for non-therapeutic means contributes to the spread of resistance, 
putting treatment options for livestock at risk as well. Treatment failure in animals due to 
drug-resistant infections would have a significant impact on food production as well as 
food security and the economy.  
A recent economic impact study by the North American Meat Institute indicates 
that the livestock industry employs more than 1.8 million people in the United States, 
with an additional 3.6 million jobs in related industries.25 The study also estimated that, 
nationwide in 2016, the meat and poultry industry created $1.02 trillion in economic 
activity. In addition, the institute purports that the industry generates $43.96 billion in 
state taxes. If superbugs emerge among livestock (bugs that cannot be treated due to 
antibiotic-resistant organisms), the financial losses would be catastrophic. Recall the 
2015 avian influenza outbreak: the outbreak cost an estimated $3.3 billion to the 
industry—considering all sectors that were effected—and an additional $500 million in 
government spending to curtail the spread of the disease.26 More than 10 percent of egg-
                                                 
24 CDC. 
25 North American Meat Institute, accessed November 5, 2017, http://www.meatfuelsamerica.com/. 
26 Maryn McKenna, “Bird Flu Cost the U.S. $3.3 Billion and Worse Could Be Coming,” Phenomena 
(blog), July 15, 2015, http://phenomena.nationalgeographic.com/2015/07/15/bird-flu-2/. 
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laying hens and 3 percent of turkeys in the United States were culled; the government 
subsidized those losses at the tune of $190 million to farmers.27  
C. HOMELAND SECURITY RELEVANCE 
Given the homeland security enterprise’s all-hazards approach, there is a case to 
be made that antibiotic resistance should be viewed as a homeland security priority. In 
2003, the Department of Homeland Security designated the food and agriculture and the 
health-care and public health sectors as part of the nation’s critical infrastructure—
“sectors whose assets, systems, and networks, whether physical or virtual, are considered 
so vital to the United States that their incapacitation or destruction would have a 
debilitating effect on security, national economic security, national public health or 
safety, or any combination thereof.”28  
The following literature review evaluates information from varied sources, 
including reports from government, public health and health-care experts, academia, and 
national and international health organizations. 
1. Characterization of Antibiotic Resistance as a Crisis 
Many public health organizations and health researchers refer to antibiotic 
resistance as a crisis, or a situation that is becoming dire. For example, the CDC asserts 
that health officials across the globe believe antibiotic-resistant organisms pose “a 
catastrophic threat” to the world.29 The World Health Organization calls antimicrobial 
(including bacteria) resistance a “global health security threat that requires concerted 
cross-sectional action by governments and society as a whole.”30 In fact, drug-resistant 
bacteria have been labeled as a threat to the public’s health by the Infectious Disease 
Society of America, the National Academy of Medicine, the American Medical 
                                                 
27 McKenna. 
28 “Critical Infrastructure Sectors,” DHS, March 5, 2013, https://www.dhs.gov/critical-infrastructure-
sectors. 
29 CDC, “Antibiotic Resistance Threats,” 11. 
30 World Health Organization, “Antimicrobial Resistance.” 
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Association, and the United Nations.31 Many scholarly works also take a doomsday tone 
when discussing antibiotic resistance: some call it a “looming public health crisis” while 
others say “it is a silent pandemic that is here to stay.”32  
In 2004, an article from the Infectious Disease Society of America described 
drug-resistant bacteria as a security issue; even more than a decade ago, all the antibiotic-
resistant organisms that existed naturally could be bio-engineered through cloning or 
forced mutation.33 The society goes on to say that research is needed to better respond to 
possible future bioterrorist attacks that could involve lab-created or engineered resistant 
organisms. The other security concern mentioned in this article is that the effectiveness of 
existing antibiotics during a future bioterrorism incident may be limited if the pathogens 
are resistant to today’s antibiotic options.34 
Within the U.S. homeland security enterprise, antibiotic resistance is listed as a 
priority in several strategy documents. For example, the 2015 National Security Strategy 
refers to antibiotic resistance as a threat to global health security.35 Antibiotic resistance 
was outlined as an emerging threat in the Department of Homeland Security’s May 2016 
“Healthcare and Public Health Sector-Specific Plan.”36 However, the 2014 Quadrennial 
Homeland Security Review lists four priority biological threats and hazards: pathogens 
                                                 
31 “IDSA: Facts about Antibiotic Resistance,” Infectious Diseases Society of America (IDSA), 
accessed January 23, 2017, http://www.idsociety.org/AR_Facts/; Brad Spellberg et al., “Antibiotic 
Resistance in Humans and Animals” (discussion paper, National Academy of Medicine, 2016), 
https://nam.edu/wp-content/uploads/2016/07/Antibiotic-Resistance-in-Humans-and-Animals.pdf; “AMA 
Continues Efforts to Combat Antibiotic Resistance,” American Medical Association, November 16, 2015, 
https://www.ama-assn.org/ama-continues-efforts-combat-antibiotic-resistance. 
32 Landers et al., “Review of Antibiotic Use”; Dušan Jasovský et al., “Antimicrobial Resistance—A 
Threat to the World’s Sustainable Development,” Upsala Journal of Medical Sciences 121, no. 3 (August 
2016): 159–64, https://doi.org/10.1080/03009734.2016.1195900. 
33 IDSA, Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates … A Public Health Crisis Brews 
(Alexandria, VA: Infectious Diseases Society of America, 2004), http://mobile.cafescicolorado.org/Bad% 
20Bugs%20No%20Drugs%20IDSA%20White%20Paper%20Jul%202004.pdf. 
34 IDSA. 
35 The White House, 2015 National Security Strategy (Washington, DC: The White House, 2015), 13–
14, https://www.whitehouse.gov/sites/default/files/docs/2015_national_security_strategy.pdf. 
36 DHS, “Healthcare and Public Health Sector-Specific Plan” (planning document, Department of 
Homeland Security, May 2016), 15, https://www.dhs.gov/sites/default/files/publications/nipp-ssp-
healthcare-public-health-2015-508.pdf. 
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that pose bioterrorism concerns, emerging infectious diseases, bioterrorist contamination 
of the food supply chain and/or water systems, and animal diseases and plant pathogens 
or pests that are highly disruptive.37 Noticeably absent from this list is antibiotic 
resistance.  
Most literature reviewed for this thesis characterizes antibiotic resistance as a 
threat to human health. It is widely recognized and could be classified as common 
knowledge. A wide and thorough search for material with a counter-argument—that 
antibiotic resistance does not pose a threat to human health—produced no results. There 
is, however, much debate on the causes of antibiotic resistance and whether certain uses 
exacerbate the problem or increase the risk to human health. 
2. Antibiotic Resistance in Food Animals 
The literature agrees that antibiotics are widely used as growth promoters for 
livestock. However, there is disagreement about the reliability of data on antibiotic 
dosage and frequency of use in agriculture. In addition, there is debate about the degree 
of risk this use poses to human health. Many studies indicate that there may be a 
significant risk, while others were inconclusive.38 It is nearly impossible to make a 
scientific claim of risk in this regard; studies would need to be conducted for each type of 
bacteria and every possible transmission route. Several studies, however, have examined 
the prevalence of infections among livestock to look for epidemiological links between 
food animals and antibiotic-resistant infections in humans. For example, one study 
looked at the prevalence of drug-resistant Campylobacter in poultry, swine, and cattle 
and found that unpasteurized milk is a confirmed transmission mechanism for 
                                                 
37 DHS, The 2014 Quadrennial Homeland Security Review (Washington, DC: Department of 
Homeland Security, 2014), 47, https://www.dhs.gov/sites/default/files/publications/qhsr/a-homeland-
security-strategy-for-countering-biological-threats-and-hazards.pdf. 
38 Landers et al., “Review of Antibiotic Use.” 
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tetracycline-resistant Campylobacter infections.39 Other example studies are provided in 
later chapters of this thesis.  
3. Health and Economic Burden of Antibiotic Resistance 
The current public health literature describes antibiotic-resistant infections as a 
substantial health and economic burden. Patients with infections caused by antibiotic-
resistant bacteria tend to be hospitalized longer and have a higher risk of poor health 
outcomes or death.40 There is less concrete information available, however, regarding the 
economic impacts of antibiotic resistance. The estimates vary, but there appears to be 
consensus that the cost of treating antibiotic-resistant infections places a significant 
burden on society. The CDC indicates the total economic burden placed on the U.S. 
economy due to antibiotic-resistant infections may be as high as $20 billion a year in 
health-care costs, and $35 billion in lost productivity.41 And, according to estimates, it 
costs $19,000 to $29,000 to treat each patient for an antibiotic-resistant infection.42 Still, 
the World Health Organization opines that there are limited studies on the matter and that 
the true impact has not adequately been measured.43 The CDC also states that the 
economic burden of antibiotic-resistant infections has been difficult to gauge, but is an 
active area of research.44  
4. Efforts in the Homeland Security Enterprise to Address the Threat 
The health-care and public health sectors are integral to cross-sector efforts to 
enhance the security and resilience of the homeland. In 1999, the Interagency Task Force 
                                                 
39 M.A. McCrackin et al., “Effect of Antimicrobial Use in Agricultural Animals on Drug-Resistant 
Foodborne Campylobacteriosis in Humans: A Systematic Literature Review,” Critical Reviews in Food 
Science and Nutrition 56, no. 13 (October 2, 2016): 2115–32, 
https://doi.org/10.1080/10408398.2015.1119798. 
40 Interagency Task Force on Antimicrobial Resistance, “A Public Health Action Plan to Combat 
Antimicrobial Resistance” (planning document, Interagency Task Force on Antimicrobial Resistance, 
2012), 8, https://www.cdc.gov/drugresistance/pdf/action-plan-2012.pdf; World Health Organization, 
“Antimicrobial Resistance.” 
41 CDC, “Antibiotic Resistance Threats,” 11. 
42 Ventola, “The Antibiotic Resistance Crisis.” 
43 World Health Organization, Antimicrobial Resistance, 12. 
44 CDC, “Antibiotic Resistance Threats,” 11. 
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on Antimicrobial Resistance was created to coordinate federal agency actions and 
accomplishments to address the public health threat of antimicrobial resistance.45 This 
task force is made up of several federal agencies, including the Department of Health and 
Human Services Office of the Assistant Secretary for Preparedness and Response, and 
the Department of Defense. The task force’s first action plan was developed in 2001 and 
has been revised several times to reflect goals to mitigate the problem. The latest report, 
“A Public Health Action Plan to Combat Antimicrobial Resistance,” published in 2012, 
outlines the goals and plans of the federal agencies that are taking steps to address 
antimicrobial resistance.46 Goals focus on surveillance, prevention and control, research, 
and new product development.  
In March 2015, the White House released the “National Action Plan for 
Combating Antibiotic-Resistant Bacteria,” which was developed in part to support the 
World Health Assembly Resolution 67.25.47 Progress toward outcomes is to be 
monitored by the U.S. government task force charged with developing the plan. The task 
force, co-chaired by the Secretaries of Defense, Agriculture, and Health and Human 
Services, is to provide annual progress updates. At a high level, the goals of the plan are 
to: 
• Slow the emergence of resistant bacteria and prevent the spread of 
resistant infections 
• Strengthen national one-health surveillance efforts to combat resistance 
• Advance the development and use of rapid and innovative diagnostic tests 
for identification and characterization of resistant bacteria 
• Accelerate basic and applied research and development for new 
antibiotics, other therapeutics, and vaccines 
                                                 
45 “The Interagency Taskforce on Antimicrobial Resistance: 10 Years of Coordinated Federal 
Action,” Center for Disease Dynamics, Economics & Policy, accessed November 10, 2018, cddep.org/ 
publications/interagency_taskforce_antimicrobial_resistance_10_years_coordinated_federal_action/. 
46 Interagency Task Force on Antimicrobial Resistance, “A Public Health Action.” 
47 The White House, National Action Plan for Combating Antibiotic-Resistant Bacteria (Washington, 
DC: The White House, March 2015), https://www.whitehouse.gov/sites/default/files/docs/national_ 
action_plan_for_combating_antibotic-resistant_bacteria.pdf; World Health Organization, “Antimicrobial 
Resistance Resolution” (committee report, Sixty-Seventh World Health Assembly, 2014), 
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• Improve international collaboration and capacities for antibiotic-resistance 
prevention, surveillance, control, and antibiotic research and 
development48 
It should be noted that since the change in presidential administration in January 2017, 
this plan has been removed from the White House’s website. It is unclear if the antibiotic 
resistance will continue to be a priority of the White House or the federal government.49 
There is agreement that antibiotic resistance is occurring, but there is also debate 
about whether or not the use of antibiotics in food animals threatens human health. Aside 
from the national and international reports on combating antibiotic resistance, this topic 
does not appear to be an area of study in homeland security academia. The homeland 
security enterprise should consider devoting more resources to addressing the threat of 
antibiotic resistance. The anthrax exposure after 9/11 accounted for a total of five deaths, 
while drug-resistant infections have accounted for tens of thousands of deaths; yet 
antibiotic resistance is considered an “emerging threat.”50 The nation’s ability to respond 
to a bioterror or other widespread disease event depends heavily on the medical 
countermeasures available to us. The over-reliance on antibiotics for non-therapeutic uses 
puts this ability to respond at risk. 
D. RESEARCH QUESTION 
Have agriculture policies implemented abroad slowed the rate of antibiotic 
resistance and could they be implemented in the United States as a homeland security 
measure?  
                                                 
48 White House, National Action Plan, 3. 
49 Search results for “Antibiotic Resistance,” The White House, accessed April 30, 2017, 
https://search.usa.gov/search?query=antibiotic+resistance&op=Search&affiliate=wh. 
50 “Amerithrax or Anthrax Investigation,” Federal Bureau of Investigation, accessed January 25, 2018, 
https://www.fbi.gov/history/famous-cases/amerithrax-or-anthrax-investigation; Zhabiz Golkar, Omar 
Bagasra, and Donald Gene Pace, “Bacteriophage Therapy: A Potential Solution for the Antibiotic 
Resistance Crisis,” The Journal of Infection in Developing Countries 8, no. 2 (February 13, 2014): 129–36, 
https://doi.org/10.3855/jidc.3573; DHS, “Healthcare and Public Health Plan,” 15. 
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E. METHODOLOGY 
Because the goal of this thesis is to provide recommendations for policies and 
agricultural practices that will help the United States slow the threat of antibiotic 
resistance, analysis of various potential policy options was conducted using illustrative 
case studies. This hybrid model of policy options analysis and case study methodology is 
well suited for this research because current policies to address this problem in the United 
States are few and have not been implemented at a national level. Analysis included 
policies gleaned from abroad as well as local examples. 
Using the CDC’s policy analysis framework, polices were selected for this thesis 
using the following framing questions: 
• What is the policy lever—is it legislative, administrative, regulatory, 
other? 
• What level of government or institution has implemented the policy? 
• How does the policy work/operate? (e.g., Is it mandatory? Is enforcement 
necessary? How is it funded? Who is responsible for administering the 
policy?) 
• What is the legal landscape surrounding the policy? (e.g., court rulings) 
• What is the historical context? (e.g., Has the policy been debated?)51  
Polices were selected from abroad that were legislatively implemented at a 
national level and that had considerable information available to summarize the context 
and history leading up to the implementation—as well as information that provides 
sufficient assessment data. Denmark and the Netherlands met these criteria. The 
researcher also included two policies that have been implemented at the state level in the 
United States to contextualize the types of legislation that have been passed for this topic 
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domestically. This thesis also reviews current national efforts to curb the threat of 
antibiotic resistance.  
Themes and patterns emerged from these case studies, which resulted in four 
proposed policy packages to implement in the United States. Again using the CDC’s 
policy analytical framework, the proposed U.S. policy packages were analyzed based on 
the following criteria: 
• Potential for the policy to impact risk factors: 
o How does the policy address the problem or issue? 
o What are the magnitude, reach, and distribution of benefit and burden? 
 What populations have benefitted? How much? When? 
 What populations have been negatively impacted? How much? 
When? 
 Has this policy impacted health disparities/health equity? How? 
o Are there gaps in the data/evidence-base? 
• Likelihood that the policy can be successfully adopted and implemented 
o Political 
 What are the current political forces, including political history, 
environment, and policy debate? 
 Who are the stakeholders, including supporters and opponents? 
What are their interests and values? 
 What are the potential social, educational, and cultural perspectives 
associated with the policy option (e.g., lack of knowledge, fear of 
change, force of habit)? 
 What are the potential impacts of the policy on other sectors and 
high-priority issues (e.g., sustainability, economic impact)? 
o Operational 
 What are the resource, capacity, and technical needs developing, 
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enacting, and implementing the policy? 
 How much time is needed for the policy to be enacted, 
implemented, and enforced? 
 How scalable, flexible, and transferable is the policy? 
• Comparison of the costs to enact, implement, and enforce the policy with 
the value of the benefits 
o Budget 
 What are the costs and benefits associated with the policy, from a 
budgetary perspective? For example, for public (federal, state, 
local) and private entities to enact, implement, and enforce the 
policy? 
o Economic 
 How do costs compare to benefits (e.g., cost savings, costs averted, 
return on investment [ROI], cost-effectiveness, cost-benefit 
analysis, etc.)? 
 How are costs and benefits distributed (e.g., for individuals, 
businesses, government)? 
 What is the timeline for costs and benefits? (e.g., Within a year? A 
decade?) 
 Where are there gaps in the data/evidence-base?52 
F. LIMITATIONS AND SCOPE 
This thesis uses the terms antibiotic resistance and antimicrobial resistance. 
Antimicrobials are all agents that can eliminate microorganisms, including antibiotics, 
which are a class of drugs used that kill bacteria.53 While this thesis is focused primarily 
                                                 
52 CDC. 
53 “What Is the Difference between Antibiotic and Antimicrobial Resistance,” World Health 
Organization, accessed November 10, 2018, http://www.emro.who.int/health-topics/drug-resistance/what-
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on policies that aim to slow the threat of antibiotic resistance, many of the examples used 
have focused more broadly on slowing the threat of all antimicrobial resistance, not only 
bacteria. 
This thesis is also focused primarily on antibiotics used for non-therapeutic 
purposes in food animals; however, this is a much larger problem that should be 
examined and solved holistically. This thesis does not review polices aimed at the use of 
antibiotics in companion animals (i.e., pets) or the environmental impacts of agriculture 
manure spreading where resistance genes persist, and where wildlife can spread resistant 
organisms. This thesis does not address the use of antibiotics for disease prevention in 
fish farms, nor does it discuss antibiotic resistance in humans and the use of antibiotics in 
clinical settings or for human health. Policymakers can use this thesis for ideas to slow 
the threat in one area where antibiotics are used.  
G. THESIS OUTLINE 
Chapters II through IV present case studies of policies enacted in Denmark and 
the Netherlands, along with national-level U.S. strategies, to slow the threat of antibiotic 
resistance. Chapter V discusses policies enacted domestically in California and Maryland. 
Next, Chapter VI compares aspects of the different policies in each of the case studies 
and identifies themes, differences, and potential gaps. Finally, Chapter VII discusses 
various policy options for the United States with an analysis of each policy package, and 
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II. CASE STUDY: DENMARK 
European countries have been banning antibiotics to promote growth in livestock 
since at least the 1960s, but those bans were aimed at specific drugs rather than classes of 
drugs.54 In 1974, scientists in the United States discovered that after poultry were given 
feed that contained the antibiotic oxytetracycline, drug-resistant bacteria dominated 
within the chickens’ intestinal flora.55 Six months later, people exposed on the farm also 
carried the drug-resistant bacteria, and they overtook 80 percent of the humans’ intestinal 
flora as well. Interestingly, the bacteria in both the humans and poultry were resistant to 
multiple antibiotics, not just the oxytetracycline. After the laced feed was withdrawn, the 
humans no longer carried the resistant bacteria. Shortly after this study, Europe banned 
the use of tetracyclines as growth promoters in livestock; however, the United States as a 
nation has not.56 This chapter examines the measures taken in Denmark in addition to 
this ban to further decrease the use of antibiotics for agricultural purposes as a potential 
solution to curbing the threat of antibiotic resistance.  
In 1990, Denmark passed legislation that limited veterinarians’ capacity to 
dispense veterinary products, including antibiotics.57 According to Denmark’s Ministry 
of Environment and Food, 
Antibiotics may only be used for production animals, if the veterinarian 
has diagnosed an infection which justifies its use. Veterinarians may only 
on certain conditions supply or prescribe antibiotics for use by the farmer, 
and the farmer must follow the advice and instructions given by the 
veterinarian. Instructions must be given in writing and must include 
identification of target animals, diagnosis, drug and dosage, clinical 
symptoms that must be observed before treatment, withdrawal period, and 
administration route. The veterinarian may only distribute or prescribe 
                                                 
54 Sharon Levy, “Reduced Antibiotic Use in Livestock: How Denmark Tackled Resistance,” 
Environmental Health Perspectives 122, no. 6 (June 2014): A160–65, https://ehp.niehs.nih.gov/122-a160/. 
55 Levy. 
56 Levy. 
57 “Distribution and Use of Veterinary Drugs in Denmark,” Danish Veterinary and Food 
Administration (DVFA), last modified May 11, 2017, https://www.foedevarestyrelsen.dk:443/english/ 
Animal/AnimalHealth/Veterinary_medicine/Pages/default.aspx. 
20 
antibiotics for the farmer’s continued treatment of diseased animals, 
except for adult cattle, for a maximum of 5 days.58 
In the early 1990s, Denmark scientists discovered the link between the use of 
avoparcin as a growth-promoting antibiotic and emerging bacteria that were resistant to 
vancomycin—another type of antibiotic that is used to treat seriously ill people.59 
Because these findings illuminated a serious threat to public health, Denmark banned the 
use of avoparcin as a growth promoter in May 1995 and the Commission of the European 
Union followed suit in 1997. In response to concerns that the growth promoter 
vieriniamycin contributed to antibiotic resistance, it too was banned in 1998. Within 
months of this ban and in response to public concerns, the cattle and poultry industries 
volunteered to stop using all growth promoters; the pork industry followed suit about a 
year later.60 
Denmark banned the use of antibiotics for growth promotion in the late 1990s and 
currently all antibiotics used in animals produced for food must be dispensed under the 
prescribed orders of a veterinarian, through a pharmacy.61 In addition, veterinarians are 
not permitted to profit from antibiotic sales.62 Denmark also implemented an extensive 
monitoring system to keep track of the sale and use of antibiotics, along with a strong 
surveillance system that detects the occurrence of resistant bacteria in food animals.63  
                                                 
58 Danish Veterinary and Food Administration. 
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A. MONITORING RESISTANCE: INTEGRATED ANTIMICROBIAL 
RESISTANCE MONITORING AND RESEARCH PROGRAMME 
(DANMAP) 
The Integrated Antimicrobial Resistance Monitoring and Research Programme 
(DANMAP) was formed in 1995 by the Danish Ministry of Food Agriculture and 
Fisheries and the Danish Ministry of Health.64 According to its website, the program was 
established with the following objectives: 
• To monitor the consumption of antimicrobial agents for food animals and 
humans 
• To monitor the occurrence of antimicrobial resistance in bacteria isolated 
from food animals, food of animal origin and humans 
• To study associates between antimicrobial consumption and antimicrobial 
resistance 
• To identify routes of transmission and areas for further research studies65  
The program seeks to monitor trends and identify potential contributing factors to 
antibiotic resistance and the spread of resistant organisms. Because animals and humans 
can spread resistant organisms to one another, DANMAP insists on an integrated 
monitoring approach.66 Denmark was the first country to establish a surveillance system 
for the use of antimicrobials.67 Agencies involved in the program are the National 
Veterinary Institute and the National Food Institute, both affiliated with the Technical 
University of Denmark, and Statens Serum Institut, which is the national governmental 
public health entity responsible for infectious disease preparedness under the Danish 
Ministry of Health.68 The program is a jointly funded effort by the Danish Ministry of 
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Health, the Ministry of Food Agriculture and Fisheries, and the Ministry of Science, 
Innovation and Higher Education.69  
The National Food Institute obtains isolates from food animals through veterinary 
practices, private labs, and slaughter plants and sends data to DANMAP.70 The institute 
also receives data from the Danish Veterinary and Food Administration, which obtains 
isolates from regional food control labs to send to DANMAP. On the human side, the 
Statens Serum Institut receives isolates and data from regional hospital labs and samples 
from general practice. Human data are then compiled and sent to DANMAP.71 The 
program also receives data from the Danish Medicine Agency and a program called 
VetStat. VetStat began in 2000 and collects data on the prescribed medicine used in 
animals.72 Veterinarians, pharmacies, and feed mills are required to report all 
administration of drugs for animal use each month.73 The data for this system are 
gathered automatically through billing mechanisms and the system then aggregates data 
by farm, including by animal species, age, disease, drugs used and amount, date of 
purchase, and the prescribing veterinarian.74 All of the data are produced in DANMAP’s 
annual report, and they allow scientists to evaluate the ban on growth promoters in the 
country as well as other policies implemented to reduce the use of antimicrobials.75 The 
information also helps analysts to identify emerging health threats and therefore to 
persuade industry to use antimicrobials judiciously.  
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One of the unique aspects of DANMAP is that it separates risk assessment from 
risk management—meaning scientists assess risks while the government entities 
implement risk management.76 This system ensures evidence-based decision-making, 
since the data are readily available and appear to be a trusted source of information in the 
country. Everyone has access to the data, which allows all stakeholders to have the same 
information when assessing interventions.  
B. ASSESSMENT 
The World Health Organization published an evaluation of Denmark’s progress in 
2003, roughly five years after the country banned antimicrobial growth promoters. The 
review examined impacts of the policies on the use of antimicrobial growth promoters, 
the ban’s effect on antimicrobial resistance, and the impact of the ban on human health, 
animal health, the environment, animal production, and the economy.77 As expected, the 
use of antimicrobials in food animals dropped significantly following the ban—a 
decrease of 54 percent from 1994 to 2001.78 The study noted an increase in the use of 
therapeutic antimicrobials in pigs following the ban due to increased diarrhea in weaning 
pigs; however, no increase was recorded for therapeutic use in poultry. Denmark’s 
surveillance system showed that, with the ban, the country was able to significantly 
reduce antibiotic-resistant Enterococci in food animals (an organism that can cause 
surgical wound infections and urinary tract infections). Due to data limitations, however, 
the authors of the study could not completely determine the impact of the ban on human 
carriage of antimicrobial-resistant organisms.79   
The World Health Organization panel found that pork production in Denmark 
increased after the ban, even though there was some loss in weaning productivity.80 No 
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major effect was found in the finishers. The study showed a small decrease in feed 
efficiency in poultry after the ban but noted that it was offset by the fact that producers no 
longer needed to purchase growth promoters. The report also outlined an increase in pork 
production costs of slightly more than 1 percent or 7.75 DKK; there was virtually no net 
increase for poultry production and the ban did not adversely impact the Danish economy 
overall.81  
1. Impacts of the Ban on Industry  
The World Health Organization concluded that the ban of antimicrobial growth 
promoters reduced resistance in food animals and “there have been no serious negative 
effects” on production, price, animal health, or food safety in Denmark as a result of the 
ban.82 The authors recommended that the issues with diarrhea in weaning pigs be 
addressed. They also suggested that more non-antimicrobial strategies would be needed 
to improve production efficiency.  
Not all the news was perceived as good, however. An Iowa State University study 
published in 2003 (funded by the U.S. National Pork Board) confirmed that even though 
antibiotic growth promoters were no longer used, antibiotic use increased for therapeutic 
purposes for two reasons: weaning piglets were contracting more illnesses and 
“therapeutic medications were increasingly substituted for the now-banned AGPs.”83 The 
study also reported that “the policy resulted in an increase in the use of the products about 
which humans are most concerned.”84 They found that the growth-promotion products 
that were banned were not as harmful to human health as the antibiotics that producers 
were using as substitutes either for the banned products or for therapeutic use after the 
ban. The authors argue, “This is a classic example of how a policy prescription can have 
consequences that are exactly the opposite of those intended.”85 The authors also 
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concluded that the economic effects included a 4.5-percent increase in production costs 
during the first year of the ban. This study assumed that production would continue to 
decline years after the ban and that some producers may need to quit the business. They 
authors further opined: 
In general, the Danes achieved 80 percent of the benefits for 20 percent of 
the costs when they imposed a partial ban, and they encountered 20 
percent of the benefits and 80 percent of the costs when they extended the 
ban.86  
This study is used often by food animal producers to lobby against growth promoter bans 
in the United States.  
There has been some rebuttal to the Iowa State University study, including from a 
former director of the National Food Institute at the Technical University of Denmark, 
Jørgen Schlundt. During an interview for an article in the June 2014 issue of 
Environmental Health Perspectives, Schlundt shared his experiences talking to people 
from the United States about antimicrobial resistance and the Danish policies.87 Given 
that Denmark’s farming culture is largely based on co-ops, he feels compelled to begin 
conversations “by saying that the Danes aren’t communists,” and by reminding others 
that the policies are based in science and on well-supported evidence.88 Interestingly, he 
noted that many of the Danish researchers were trained in the United States by the CDC.  
Also important to note is a Danish study published in 2010 that evaluated the 
changes in antimicrobial consumption and productivity on Denmark’s swine farms by 
examining their use of antimicrobials from 1992 to 2008.89 The researchers concluded 
that antimicrobial use per kilogram of pig in the country decreased by more than 50 
percent during that time period and that there was an improvement in productivity—the 
number of swine in the Danish swine industry increased. In addition, the number of pigs 
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per litter per sow also increased. The mortality rate for all pigs did not appear to be 
affected. These findings suggest that productivity was not negatively impacted by the ban 
on growth promoters.90 Therefore, the long-term effects predicted by the Iowa State 
University study authors are inaccurate; counter to the study’s predictions, the Danish 
pork industry is flourishing. 
2. The Yellow Card Initiative 
Surveillance data indicates that during the period after the ban, from 2001 to 
2009, consumption of antibiotics in all animal sectors was up 45 percent, with 80 percent 
of those antibiotics used in swine production, which aligns with the findings of the Iowa 
State University study mentioned previously.91 The authorities recognized that there was 
an increase in therapeutic use of antibiotics after the removal of growth promoters among 
weaning pigs.92 There was also a concurrent Lawsonia intercellularis outbreak that may 
have contributed to the increase in therapeutic use.93 Also over that time period, cases of 
post-weaning multisystemic wasting syndrome were increasing, which likely contributed 
to the use of antimicrobials. Antimicrobial use continued to increase even ten years after 
the ban; however, researchers concluded that it was highly unlikely the increase was 
caused by the removal of growth promoters.94  
In response to this trend of increasing antibiotic use, the Danish Veterinary and 
Food Administration (DVFA) created the yellow card initiative. Instituted in 2010, the 
initiative was aimed at reducing the consumption of antibiotics by 10 percent by 2013.95 
Under the initiative, farms with herds exceeding the threshold of antibiotics per 100 
animals per day in a nine-month period will be inspected by veterinarians and the farmer 
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will be issued a yellow card warning. The warning compels the owner to reduce the 
consumption below the threshold limits within nine months. The producer can also be 
forbidden to use any antibiotics they may have in their possession if a particular type has 
been prescribed several times and is given through feed or water.96 Inspections by the 
DVFA are unannounced during the nine-month period.  
If after nine months the antibiotic consumption has not been reduced below the 
threshold limits, or if it was reduced below the maximum limits and then again rose 
above the limits in the twelve months after the first yellow card period, the DVFA may 
issue another injunction calling for increased supervision.97 This injunction compels the 
producer to receive guidance from another veterinarian who will advise on how to reduce 
antibiotic use, at the farmer’s expense. This injunction lasts five months and the DVFA 
may inspect the farm unannounced. A red card is issued if the farm has not reduced 
consumption below the maximum limits within five months of the second injunction. For 
a red card injunction, the DVFA my force the farmer to reduce his or her stock to ensure 
antibiotic consumption is within the acceptable levels. This injunction cannot be lifted 
until the DVFA confirms through inspections that the consumption is below the threshold 
limits.98 There are economic impacts to the farms for not complying with these 
thresholds: the producer must pay a fine for each injunction, and all inspection visits are 
at the expense of the farmer.  
The yellow card initiative appears to be an effective method of reducing antibiotic 
consumption. By 2013, a 10.2-percent reduction was achieved.99 The Danes have issued 
an action plan to combat livestock-associated MRSA by reducing consumption for swine 
by 15 percent between 2015 and 2018.100  
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3. Current Status of Resistant Zoonotic Bacteria in Denmark 
In its 2016 report, the Danish Surveillance system, DANMAP, highlighted 
findings related to resistance in zoonotic bacteria.101 Because of the restrictive use of 
“medically important” antibiotics in swine farming, the report states, the most prevalent 
Salmonella serotype among Danish pigs, Salmonella typhimurium, has not been found to 
be resistant to fluoroquinolone (ciprofloxacin), an antibiotic used to treat bacterial 
infections in humans.102 The reports also states that S. typhimurium was the most 
common Salmonella serotype among human isolates that were tested for susceptibility to 
antibiotic resistance. Interestingly, for those who acquired the infections domestically, the 
tetracycline resistance increased from 55 percent in 2015 to 68 percent in 2016; however, 
both ciprofloxacin and nalidixic acid resistance were higher in isolates from individuals 
who acquired their infections while traveling outside Denmark.103  
The report also noted that, among broiler chickens’ isolates, fluoroquinolone-
resistant Campylobacter jejuni levels appear to be higher in imported meat.104 However, 
the group reports an increase of the levels of fluoroquinolone resistance among cattle 
isolates even though these antimicrobials are very rarely used in cattle.105 The human 
findings are similar to that of S. typhimurium in that more isolates in people who traveled 
were found to be resistant than in those whose infections were acquired locally.106  
Taken together, the DVFA and DANMAP studies show that with reduction in use 
there has been some reduction in antibiotic resistance in animals, but the rates of resistant 
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infections among people have continued to increase. However, rates of resistance remain 
higher in imported meat and for individuals who have acquired their resistant infections 
outside of Denmark. This surveillance highlights the need for standard global solutions to 
this problem. 
C. IMPLEMENTATION STRATEGIES 
Denmark’s ability to implement such sweeping regulation can be attributed in 
large part to its commitment to involving stakeholders and keeping the discussions and 
data about the situation transparent to the public.107 The country also achieved greater 
buy-in for the policy changes by having independent third parties conduct the research. 
The government employed media campaigns to help convince the public of the risks 
associated with antimicrobials as growth promoters and to promote the good that 
producers are doing for the country and the world by not using growth promoters.108 
Many sectors of Denmark’s agricultural industry are organized into co-ops, and many 
farmers are co-owners of slaughterhouses, which means that the industry was poised to 
work together to respond to pressures from the public, which may have promoted 
acceptance of the country’s regulatory measures.109 
In addition, because of the shift away from antibiotics in veterinary practices, 
enhanced biosecurity measures were needed. Specifically, all-in/all-out strategies were 
employed to reduce disease transmission.110 This management practice ensures that 
infection from other animals is eliminated by keeping swine isolated in groups while on 
the farm. The groups are not mixed and when they move through the various production 
stages, the sites on the farms are completely emptied out and cleaned. Farmers also report 
allowing pigs to nurse longer to allow natural immunity to build up before they are 
moved to the next production stage.111 
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Key to the Danes’ ability to inform its policy decisions was the creation of 
DANMAP. This monitoring program allows the Danish government to perform 
surveillance on antimicrobial distribution and use and to track resistance patterns in the 
country. Without it, the government would not know what policy decisions are needed or 
whether its interventions have affected antibiotic use or resistance.  
Denmark’s ban on antibiotic growth promoters did not appear to impact industry 
and did show some success. The rates of vancomycin-resistant Enterococci (VRE) in pigs 
and poultry were reduced, yet there is no evidence that the rates were reduced in humans; 
VRE in humans is genetically different from the same bacteria typically found in 
animals.112 Resistance to avoparcin and erythromycin decreased after the ban.113  
The ban also had some unintended consequences: for instance, there was an 
increase in therapeutic antibiotic use among weaning pigs shortly after the ban. It is 
unclear if this increase is simply because there were more animals present, or if more 
infections were occurring. There is no evidence that the industry is using the antibiotics 
illegally—such as for routine disease prevention. It is possible that other factors are 
accelerating antibiotic resistance outside of drug use, like the use of copper and zinc in 
feed. 
The Danish government understands that the fight against antibiotic resistance is 
far from over. Because of increasing consumption, the country has instituted goals to 
reduce the overall use of antibiotics in agriculture.114 DANMAP’s surveillance also 
indicates that global solutions are needed given that imported meat and isolates from 
humans show greater resistance to antimicrobials than those in Denmark. 
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III. CASE STUDY: THE NETHERLANDS  
Livestock producers in the Netherlands have not been able to use growth 
promoters since 2006, when the European Union banned the use of most antibiotics for 
this purpose. Even after the ban, however, the Netherlands was the top-ranked country for 
antibiotic use in agriculture.115 This chapter describes the steps the Dutch have taken to 
curb antibiotic use and the effects of their more conservative approach. 
A. THREATS AND CONCERNS EMERGE 
Microbial resistance levels in the Netherlands have traditionally been low in 
health-care settings and the country’s use of antibiotics in human medicine is among the 
lowest in Europe.116 But, as Europe’s leading meat exporter, the Dutch have also used 
large amounts of antibiotics in animal production and resistance levels are high.117 The 
Dutch began to express concern in 2004, prior to the effective date of the European ban 
on growth promoters, when methicillin-resistant Staphylococcus aureus (MRSA)—a 
hard-to-treat, antibiotic-resistant organism—was detected in a young girl who lived on a 
swine farm.118 Finding this organism in the Netherlands at the time was extremely 
uncommon, and MRSA rates in the country were among the lowest in Europe.119 The 
patient’s family members were found to be carriers of this organism, and so too were 
friends of the family. The same strain was confirmed in their pigs.120  
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Scientists quickly went to work to investigate pig farming as a source of MRSA in 
the Netherlands. A 2005 study found that other pork producers and their families were 
also carrying the organism.121 In one instance, the organism was found in the son of a 
veterinarian whose primary patients were pigs; it was also transmitted to a nurse who 
cared for the veterinarian’s son in the hospital.122 Ultimately, this research demonstrated 
that people in the study area who came in contact with pigs had MRSA at a frequency 
760 times higher than the general Dutch population.123 Fearing the spread of MRSA in 
hospitals, doctors treat individuals who are at higher risk to carry the organism in 
isolation rooms until test results indicate they are not colonized or infected.124  
Given the public health implications posed by the MRSA situation, Dutch 
authorities began discussing what could be done to reduce the use of antimicrobials in 
veterinary practice in the Netherlands, even after the European antibiotic growth 
promoter ban was enacted. In 2008, the country convened a task force aimed at tackling 
antibiotic resistance in animal husbandry.125 The members of the task force included 
industry stakeholders as well as the Royal Dutch Veterinary Association (KNMvD), the 
Dutch Ministry of Agriculture, and the Dutch Ministry of Health.126 The group put 
together action plans through memoranda of understanding, which described measures to 
reduce antibiotic use and monitor resistance, and outlined a separation of duties between 
farmers and veterinarians with regard to prescribing antibiotics.127 
While this work was being conducted, another threat emerged—extended 
spectrum beta-lactamase-producing bacteria (ESBLs) were discovered in Dutch poultry 
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meat in 2009.128 EBSLs produce an enzyme that makes antibiotics ineffective. Strains of 
Escherichia coli (E. coli) and Klebsiella pneumoniae are the most common ESBLs.129  
As with pig production, antibiotic use was also heavy in the poultry industry in 
the Netherlands. Given the increase in infections caused by ESBLs among patients in 
Dutch hospitals, scientists began looking at the prevalence of these bacteria in livestock 
production. One study looked at twenty-six boiler chicken farms and found that all 
animals were shedding ESBL-producing E.coli in their feces.130 That meant that virtually 
all broiler meat products studied during this research were positive for ESBL-producing 
organisms. After the study, poultry farms were considered a source of ESBL-producing 
gram-negative bacteria. Shortly after, an investigation from the University Medical 
Center Utrecht revealed that poultry meat was a likely route of bacteria transmission to 
humans.131 The findings were disseminated in the media, resulting in concern from 
Dutch citizens.132  
Agricultural antibiotic use in the country was still high, even though the 
Netherlands adopted the European growth promoter ban. Much like in Denmark, Dutch 
sales data indicated that the country resorted to using more antibiotics after the ban for 
what was cited as therapeutic reasons—meaning drugs were reportedly used to treat sick 
animals.133 In fact, one study showed that the Netherlands consumed the most antibiotics 
out of ten European countries in 2007.134 The cited therapeutic uses ranged from 
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treatment of disease to feed quality; non-infectious disease and changes in farming 
practices also contributed to the increase in use.135  
B. FURTHER ACTION TAKEN TO REDUCE ANTIBIOTIC USE IN FARM 
ANIMALS 
Because of added public pressure to address the problem, the Dutch government 
continued its debate on the high levels of antibiotic use in food animals.136 Although the 
memos released previously did not specifically outline goals for reducing antibiotic use, 
in 2010 the government began instituting mandatory reduction targets.137 The goal was, 
based on 2009 levels, to reduce the use of antibiotics by 20 percent by 2011, 50 percent 
by 2013, and 70 percent by 2015.138  
In August 2011, the Dutch Health Council, which describes itself as an 
“independent scientific advisory body for government and parliament,” advised the 
Dutch government to ban newly developed antibacterial drugs, along with third- and 
fourth-generation cephalosporins and fluoroquinolones, for animals.139 The council also 
recommended banning the drug colistin and phasing out the use of β-lactam antibiotics 
and aminoglycosides in animals.140 Ultimately, the Dutch government decided to adopt 
the recommendation of restricting the use of third- and fourth-generation generation 
cephalosporins and fluoroquinolones in animal husbandry.  
An antibiotics policy working group of the Dutch Royal Veterinary Association 
also crafted guidance for the use of antimicrobials in terms of first, second, and third 
choices for veterinary treatment purposes.141 In 2013, requirements changed: farmers 
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could now only store first-choice drugs onsite for empiric treatment (i.e., before it is 
known which bacterium is infecting the animals).142 These drugs must be used in 
accordance with a mandatory treatment plan, which must be created with a veterinarian 
and based on guidelines from the Netherlands Veterinary Medicines Institute (SDa).  
1. Dispensing Antibiotics 
The Netherlands recognized that veterinary interests and the interests of farmers 
may be at odds with the goal of reducing antibiotic use.143 In addition to the enacted 
regulatory bans, the Dutch government proposed changes to the way antibiotics were 
dispensed in the country. Antibiotics can only be obtained with a prescription from a 
veterinarian, and veterinarians are also responsible for dispensing the drugs.144 To 
address continuity issues, in 2012 the government began requiring farmers to partner with 
only one veterinary practice.145 Veterinarians are also required to inspect the farm before 
they can prescribe antibiotics to ill livestock—and only under strict conditions can 
second- and third-choice antimicrobials be used in animals.146  
To address conflict-of-interest issues with veterinarians, in 2011 the KNMvD—
the professional veterinary association in the Netherlands—proposed a quality system for 
veterinarians that would include treatment guidelines, as well as a register where 
veterinarians could pursue accredited continuing education courses.147 The system, 
referred to as the “approved veterinarian,” requires veterinarians to abide by the treatment 
guidelines and create farm-specific animal health and treatment plans, creating a one-on-
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one relationship with farmers.148 The KNMvD created a basic quality register for all 
veterinarians and has also compiled several specialty-specific, private quality registers. 
These registers list veterinarians who meet the criteria to be listed as approved 
veterinarians for that particular sector.149  
2. Monitoring Antibiotic Use and Resistance 
Since 2012, veterinarians and livestock farmers have been required to report all 
antibiotics administered to farm animals to the SDa.150 The SDa, the Netherlands 
Veterinary Medicines Institute, is a public-private entity that monitors the amount of 
antibiotics used by each Dutch livestock sector and examines the amount of antibiotics 
sold against the number of antibiotics used. The agency issues an annual report that 
displays trends in use and sales by livestock sector with a focus on critically important 
antibiotics. The report also includes the best information available on unmonitored 
sectors, such as some poultry-farming sectors, mink, sheep, goats, zoos, companion 
animals, and horses.  
C. ASSESSMENT 
In addition to its monitoring responsibility, the SDa is responsible for setting 
antibiotic-use reduction targets for each food-animal species. The organization includes 
an independent expert panel comprising veterinary scientists, epidemiologists, and 
human-medicine scientists. The panel reviews veterinary prescribing patterns as well as 
antibiotic use on farms and then uses the data to establish benchmarks for the types and 
quantities of antibiotics that should be used for each sector.151 The SDa’s website states 
that it strives to meet multiple goals: 
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The SDa’s final goal is not merely to realize a reduction in antibiotic use, 
but rather to restrict the usage of antibiotics in animals in such a way as to 
minimize the associated public health risks. To this end, the SDa defines 
specific target values for antibiotic use. To achieve the final goal, animal 
husbandries should increasingly focus on developing good practices for 
farm-oriented and chain-oriented animal health management and infection 
control, as this is the only way to become less dependent on antibiotics.152 
The SDa reports on the status of antimicrobial use in pigs, veal, cattle, broiler 
chickens, turkeys, and meat-rabbit farming sectors. In 2013, the SDa’s goal was to cut 
antibiotic use in half compared to 2012 levels, which were already lower than previous 
years.153 That said, it does not appear that the 2015 goal of an overall 70 percent 
reduction was met, nor was it met in any of the monitored livestock sectors. The SDa 
reported in 2015 that the veal farming sector had reduced its use of antibiotics by 
35 percent since 2009; pig farmers were able to reduce their use by 56 percent, the broiler 
chicken sector by 60 percent, and dairy cattle farmers by 46 percent.154 In its 2016 
report, the SDa stated that the number of kilograms of antimicrobials sold declined by 
64.4 percent between 2009 and 2016.155 The use levels among most sectors continued to 
decline, though not as sharply as the declines noted in the previous five years, indicating 
that levels may be stabilizing.156 
A 2016 report issued by the Dutch Foundation of the Working Party on Antibiotic 
Policy, in collaboration with the National Institute for Public Health and the Environment 
of the Netherlands, stated that the lowest proportion of ESBL-producing E. coli was 
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observed in random isolates of E. coli since 2007.157 The report also found that ESBL/
AmpC- prevalence in poultry meat had decreased substantially from the previous year. 
The decrease was attributed to the reduced use of antibiotics in this sector.158 The 
authors of the report conclude that the Dutch policies aimed at reducing the total use of 
antibiotics have made a substantial impact on decreased resistance in the country.159 
D. IMPACTS OF POLICIES ON INDUSTRY 
With no antibiotics available to them for use as prophylaxis, and with antibiotics 
only available after an inspection, one might conclude that farmers would have strong 
opposition to the Dutch antibiotic-use policies. Universally, however, this does not seem 
to be the case. A farmer interviewed for a National Geographic video story on the subject 
discusses how the transition was a natural one for him. After the MRSA scare, he and 
other pig farmers in his region formed a network of farmers who believed that healthy 
animals do not need antibiotics.160 The group sought to find practices that helped them 
keep their animals healthy; they learned from each other what worked and shared their 
experiences with other farmers outside their immediate network. He believes it is 
important to stay the course: “You do it for yourself, for the next generation, but also to 
get more profit out of your farm.”161 The farmer sees better results now with healthy 
pigs, and notes that sick pigs do not result in any profit.  
Not all farmers found it so easy to adapt to the policies, however. In the same 
National Geographic video series, a Dutch poultry farmer discusses his experience with 
the regulations and how he struggles when his animals are sick.162 He agrees that 
                                                 
157 S. C. de Greeff, J. W. Mouton, and A. F. Hoeing, “NethMap 2016: Consumption of Antimicrobial 
Agents and Antimicrobial Resistance among Medically Important Bacteria in the Netherlands in 2015” 
(report, National Institute for Public Health and the Environment, June 2016), 14. 
158 de Greeff, Mouton, and Hoeing, 14. 
159 de Greeff, Mouton, and Hoeing, 15. 
160 Maryn McKenna, “Getting a Farm off Antibiotics,” vimeo video, posted by maryn, May 27, 2014, 
https://vimeo.com/96639425. 
161 McKenna. 
162 Maryn McKenna, “Questioning Farm Antibiotic Rules,” vimeo video, posted by maryn, May 27 
2014, https://vimeo.com/96640919. 
39 
reducing antibiotic use is very good, but because the regulations mandate which 
antibiotics must be used first, he has been prohibited from using the third-choice group of 
antibiotics (i.e., those that are medically important to humans), even when he knows they 
are going to cure the animals. You can still develop resistance, he argues, by 
administering antibiotics that do not work first, and then using the ones you knew would 
work all along. He has a hard time with the stigma associated with poultry and swine 
farmers in the country.  
As for overall impacts, in opening remarks during an international conference on 
antibiotic resistance in June 2014, the Dutch minister of agriculture reported that in three 
years the country was able to lower the rates of antibiotic use in agriculture while still 
remaining second in the world in agricultural exports.163  
E. IMPLEMENTATION STRATEGIES 
Much of the Netherlands’ success in reducing antibiotic use can be attributed to 
the government’s role in setting targets or goals for the country. The memoranda that 
were established in 2008 did not significantly reduce the use of antibiotics as growth 
promoters.164 This example demonstrates that bans on non-therapeutic use are likely not 
enough to slow resistance; only when governmental regulations with specific goals were 
enacted did the country see reductions in antibiotic use.165  
In addition, public opinion may have played a significant role in influencing 
changes in the Netherlands. The discovery of livestock as a reservoir for superbugs such 
as MRSA that are dangerous to humans—including farmers and their families—likely 
contributed to farmers’ willingness to change their practices. Producers may have also 
felt pressure from public mass media campaigns regarding MRSA and other frightening 
resistant infectious diseases. The public began seeing the potential consequences of 
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antibiotic overuse in livestock and disapproved of the practice—thus the demand for 
judicious use of antibiotics in agriculture.166 In addition, the Ministry of Economic 
Affairs notes that the policies were adopted due to the agriculture industry and 
veterinarians’ sense of urgency to respond.167 Because of this public-private partnership, 
there was widespread support, which allowed for easy adoption.168  
F. CONCLUSION 
After emergent health threats and political pressure, the Dutch implemented 
targets for reducing antibiotic use in livestock. Because of their monitoring systems, they 
understood that antibiotic use in the country remained high even after a ban on antibiotics 
as growth promotion for livestock. Industry had transitioned from growth-promotion use 
to therapeutic use—the bans were not enough to produce an overall reduction. The 
national targets and veterinary practices seem to be producing the reduction the country is 
seeking with limited impact on production.  
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IV. UNITED STATES: LEGISLATIVE EFFORTS 
AND CURRENT POLICY 
At the national level, the United States, has implemented few regulations and only 
recently has issued limited guidance related to reducing the use of medically important 
antibiotics in food animals. This chapter discusses possible reasons behind the lack of 
action as well as current strategies that have been attempted or employed.  
A. POTENTIAL LEGISLATION 
Although legislation limiting the use of antibiotics in food animals has been 
introduced in the United States, none has been enacted. This section discusses potential 
bans discussed in the past as well as legislation that has been proposed to slow the threat 
of antibiotic resistance.   
1. Historical Discussion 
In 1969, the Swann Committee—a task force established in the United Kingdom 
to review the use of antimicrobials in food production for growth promotion—determined 
that multidrug-resistant Salmonella infections may be the result of growth promotion 
antibiotics in livestock and that action should be taken to limit their use.169 Eight years 
after this report was published, the U.S. Food and Drug Administration (FDA) considered 
banning penicillins and tetracyclines for food animal use.170 The FDA had planned to 
hold hearings on the issue, citing “studies relevant to transfer of drug resistance” and 
safety concerns related to the subtherapeutic use of antibiotics in animals.171 The 
discussion was intended to focus on the lack of evidence stating that penicillin-containing 
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premixes for feed are safe or effective for use.172 The effort, however, did not progress 
beyond a congressional committee; the farm lobby prevented the hearings from taking 
place.173 According to a Frontline news report, a legislator with strong ties to the farm 
industry served on the subcommittee responsible for approving the agency’s budget.174 
Given that farmers and drug manufacturers were opposed to these changes due to limited 
scientific evidence and economic concerns, the legislator threatened to cut the FDA’s 
funding if they pushed forward. Ultimately, the secretary of the Department of Health 
and Human Services did not wish to gamble the department’s funding on this proposal 
and asked that the proposed regulations be tabled for a later date.175 That date never 
came.  
There have been several legal attempts by advocacy organizations to resurrect the 
1970s proposals, which have resulted in a continuous cycle of litigation and appeals; to 
date, the FDA has not been required to hold hearings regarding the safety of antibiotics 
used in animal feed. In 2011, the FDA formally withdrew the 1977 proposals and 
explained that the agency was committed to looking at other options to limit the use of 
growth promoters in food animals.176 The agency issued guidance for the industry in 
2012 and 2013, which is discussed later in this chapter. 
2. Preservation of Antibiotics for Medical Treatment Act (PAMTA) 
Beginning in 1999, the late Representative Louise Slaughter of New York 
cosponsored or introduced legislation several times to mitigate the risks of antibiotic 
resistance. Her last proposed legislation, the Preservation of Antibiotics for Medical 
Treatment Act of 2017 (PAMTA), would eliminate the non-therapeutic uses of medically 
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important antimicrobials in animals.177 The proposed legislation is reminiscent of the 
hearing text from the 1977 proposal. The bill reads: 
With respect to a medically important antimicrobial (as defined in 
subsection (q)), the applicant has failed to demonstrate that there is a 
reasonable certainty of no harm to human health due to the development 
of antimicrobial resistance that is attributable, in whole or in part to the 
nontherapeutic use (as defined in subsection (q)) of the medically 
important antimicrobial or drug.178 
The bill also includes a phased elimination of nontherapeutic use in animals, 
which directs the secretary of the Department of Health and Human Services to withdraw 
the approval of drugs for nontherapeutic use within two years. If the applicants, typically 
drug manufacturers, can prove that there would be no harm to human health due to 
antimicrobial resistance, the drugs could still be used for growth promotion or for 
prophylaxis.179 If the bill were to pass, it would be illegal to use a medically important 
antimicrobial in food animals for anything other than treatment of disease or significant 
risk of disease (i.e., during an outbreak). The law would also require that the dosing 
would be as minimal as necessary to prevent or reduce the risk of transmission. During 
the 113th Congress, a previous version of this bill had seventy-eight cosponsors and was 
backed by more than 450 organizations.180 Though the concept was first introduced 
nearly twenty years ago, the bill has yet to be taken up in committee.  
As discussed earlier in this chapter, the 1977 FDA proposal sowed opposition to 
any legislation or regulation of antibiotics in agriculture. On its website, the Animal 
Health Institute has compiled testimony, reports, videos, and other documentation that 
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provide an opposing viewpoint.181 The institute also published a page titled “Fact or 
Fiction: Common Antibiotic Myths” to debunk estimates of the amount of antibiotics 
used in healthy animals, the threat levels of various organisms, and the claim that 
antibiotics in animals is what causes drug resistance.182 
According to the Center for Responsive Politics, sixty-one organizations reported 
lobbying against PAMTA since 2006.183 When searching for “Preservation of 
Antibiotics for Medical Treatment Act” on the center’s website, at the top of the list of 
lobbyers are the Animal Health Institute, the National Chicken Council, the National 
Pork Producers Council, the National Milk Producers Federation, the National Turkey 
Federation, and Elanco Animal Health.184 The vast majority of the lobbying 
organizations on the list represent the agricultural and pharmaceutical industries. 
Additionally, a Healthline news story reports that Pfizer has spent close to $900,000 to 
oppose PAMTA.185 And in 2017, the Animal Health Institute alone spent $140,000 
lobbying against PAMTA.186  
In June 2018, Senators Kirsten Gillibrand, Dianne Feinstein, Elizabeth Warren, 
and Richard Blumenthal announced a bill that would require the FDA to take additional 
steps to provide oversight of medically important antibiotics and their use in animals by 
requiring the secretary of the federal Health and Human Services Department to “review 
the durations of use.”187 If the bill passes, a manufacturer would be required to justify 
approved indications for use in animals for durations greater than twenty-one days. If the 
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rationale is not considered to be “scientifically justified” or if it is found that the disease 
can be treated or prevented through other avenues after twenty-one days of treatment, the 
secretary must withdraw the approval that allows continued use.188 The bill also instructs 
the FDA to examine antibiotics delivered to farms by reporting on data collected from 
veterinary feed directives and feed distribution reports. As of the writing of this thesis, 
the bill has only been introduced in the Senate and referred to the Committee on Health, 
Education, Labor, and Pensions.189 
B. ACTION PLANS AND GUIDANCE 
While there has not yet been congressional action, the FDA and Department of 
Agriculture have joined the conversation with more urgency in recent years.  
1. Food and Drug Administration: Guidance for Industry 
In 2003, the FDA released guidance related to antimicrobial resistance. The 
document, titled “Guidance for Industry #152: Evaluating the Safety of Antimicrobial 
New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human 
Health Concern,” recommends an approach during the drug application process to 
evaluate new antimicrobial animal drugs against bacteria they are not intended to treat, 
referred to as “non-target bacteria.”190 The guidance document’s scope is limited to new 
drugs that, when used, could potentially result in resistant foodborne pathogens. The 
agency recommends a pre-application risk assessment approach for all uses of new 
antimicrobial drugs to be administered with food animals. Drug manufacturers are not 
required to use this risk-assessment process, but those who wish to are advised to submit 
a hazard characterization based on information about the drug’s bacterial resistance.191 
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The sponsor also has the opportunity to identify emerging science or gaps in data that 
may be applicable to the hazard characterization, which allows a manufacturer to indicate 
that more research is needed to fully document potential food safety hazards.192 Once the 
FDA evaluates the hazard characterization, the agency works with the sponsor to 
determine if a risk assessment should be completed.193 The final step in this process is 
the FDA’s determination of risk estimation, during which the agency alerts the sponsor to 
apply certain risk management principles when using the drug.194 
One year later, in 2004, the FDA released “Guidance for Industry #144: Pre-
approval for Registration of new Veterinary Medicinal Products for Food-Producing 
Animals with Respect to Antimicrobial Resistance.” The process detailed in the 
document is also not mandatory; it outlines recommended data types that should be used 
to characterize any potential resistance development when registering a product for use in 
food animals.195 The FDA recommends providing basic information about the drug, such 
as the class of the drug, the type of action the drug takes on the antimicrobial spectrum of 
activity, the resistance mechanism, the molecular genetic basis of resistance to the 
antimicrobial drug, occurrence and rate of transfer of resistance genes, cross-resistance, 
co-resistance, and pharmacokinetic data.196 The agency suggests that sponsors—during 
the product registration process—should focus on describing this information in relation 
to foodborne pathogens after the drug is administered to the animal.197 
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Several years later, in 2012, the FDA released guidance for industry aimed at 
addressing sensible antimicrobial use in food animals. The framework in “Guidance for 
Industry #209: The Judicious Use of Medically Important Antimicrobial Drugs in Food-
Producing Animals” is intended to limit the use of antimicrobials in food animals for 
non-therapeutic means via voluntary measures: 
In order to minimize the development of antibiotic resistance, FDA 
believes that it is important to ensure the judicious use of medically 
important antimicrobial drugs in animal agriculture. We recommend 
several steps to accomplish this including voluntary measures that would 
limit medially important antimicrobial drugs to uses in food-producing 
animals that are considered necessary for assuring animal health and that 
include veterinary oversight or consultation. Such limitations would 
reduce overall medially important antimicrobial drug use levels, thereby 
reducing antimicrobial resistance selection pressure, while still 
maintaining the availability of these drugs for appropriate use.198  
Included in the guidance is a literature review as well as a summary of scientific studies 
examining the risks of using medically important antimicrobial drugs in livestock. The 
FDA concludes that all the strategies to slow antimicrobial resistance are necessary, and 
that the agency must take a more proactive approach toward the use of medically 
important antimicrobial drugs.199  
The “Guidance for Industry #209 document” also recommends two voluntary 
principles on the judicious use of antimicrobials in livestock. The first principle states, 
“The use of medically important antimicrobial drugs in food-producing animals should 
be limited to those uses that are considered necessary for assuring animal health.”200 The 
agency opines that antimicrobials for growth promotion and feed efficiency are not 
judicious uses and encourages uses that align with prevention and treatment of disease in 
food animals. As long as a veterinarian is involved with the use of medically important 
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antimicrobial drugs, the FDA believes that use for disease prevention is appropriate. The 
second principle is, “The use of medically important antimicrobial drugs in food-
producing animals should be limited to those uses that include veterinary oversight or 
consultation.”201 The FDA believes that veterinarians should be involved in decision-
making regarding the use of antimicrobials of medical importance, and encourages a 
phased increase in veterinary involvement, again on a voluntary basis.  
A year later, the FDA issued “Guidance for Industry #213: New Animal Drugs 
and New Animal Drug Combination Products Administered in or on Medicated Feed or 
Drinking Water of Food Producing Animals: Recommendations for Drug Sponsors for 
Voluntarily Aligning Product Use Conditions with GFI #209.” This document explains 
how to submit new animal drug applications in accordance with the principles outlined in 
the #209 guidance. It defines what constitutes appropriate therapeutic use of antibiotics in 
food animals, states that veterinary oversight is needed to use antibiotics as prophylaxis, 
and specifies that any new drug uses should be accompanied by dosing duration and 
amount on the drug label.202 
In the #213 guidance, the FDA also indicates that it will work with any drug 
sponsors interested in voluntarily revising their approved drug labeling to remove 
“production” uses of their medically important antimicrobial drugs.203 The FDA 
recommends that drug manufacturers revise the status of these drugs (when they are 
included in feed), which are currently available over the counter; instead, they 
recommend veterinary oversight through a veterinary feed directive, and a prescription if 
the drugs will be included in drinking water.204 The agency recognized that the 
veterinary feed directive regulations needed to be changed to facilitate easier 
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implementation of this voluntary change and minimize adverse impacts on the 
industry.205 The FDA published a final rule in June 2015 and also issued “Guidance for 
Industry #120: Veterinary Feed Directive Regulation Questions and Answers,” which 
provided guidance on the published rule that would help the industry make the voluntary 
changes.206 
To measure if its strategy is working, the FDA reviews data, published in its 
annual summary report, on the sale and distribution of antimicrobials.207 The agency also 
largely funds the National Antimicrobial Resistance Monitoring System (NARMS), 
which collects data on antimicrobial resistance, which in turn allows the agency to review 
trends in antimicrobial resistance.208 This system is discussed later in the chapter.  
While the FDA has made an effort to provide direction on how to reduce the use 
of medically important antibiotics in U.S. livestock, the effort is strictly voluntary. On the 
FDA’s website, a page titled “Strategy on Antimicrobial Resistance, Question and 
Answers” explains that the “FDA believes that the collaborative [voluntary] approach is 
the fastest way to implement the changes outlined in Guidance #213.”209 The FDA goes 
on to say that  
initiating regulatory action would require the agency proceed on a product 
by product basis, would likely create significantly more disruption to 
animal health/agriculture industry, and would require significantly more 
resources and time to implement. This collaborative approach, as outlined 
in GFI #213, is the quickest way to achieve the greatest degree of public 
health protection.210 
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Although public health advocates were skeptical of a voluntary approach, it the FDA had 
reason to be confident about a voluntary strategy—it has successfully negotiated with all 
drug sponsors.211 This effort is discussed in greater detail later in this chapter. 
The FDA addresses the idea that animal producers could use medically important 
antimicrobials for production purposes under the guise of preventing disease; once the 
labeling is voluntarily changed, the FDA therefore says, the products can no longer be 
used in an off-label manner, including for nontherapeutic use.212 The agency also 
indicates that with oversight of licensed veterinarians, these products would not be used 
for production purposes and it would be up to a veterinarian, based on his or her training 
and knowledge, to determine when to preventively treat animals against infection.213  
Even though many advocacy and public health organizations have applauded the 
FDA’s efforts, they argue that these efforts might not go far enough. This guidance 
demonstrates only recommendations from the FDA and does not address routine use of 
antibiotics for prophylaxis without requiring evidence of a disease risk. The Pew 
Charitable Trusts have lauded the effort as an “important step in ensuring the judicious 
use of [antibiotics].”214 However, the organization also asserts that there are problems 
with the approach; Pew found that nearly 30 percent of relevant drug labels do not have 
defined durations of use—most commonly Tylosin and tetracyclines.215 The FDA 
solicited comments to establish durations of use for medically important antibiotics; the 
information was due at the end of December 2016, but it is unclear if the FDA has plans 
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to require labeling changes to include duration of use for all medically important 
antibiotics.216  
2. United States Department of Agriculture: Antimicrobial Resistance 
Action Plan 
The United States Department of Agriculture (USDA) does not have any 
regulatory authority regarding antimicrobial use in food animals; the FDA, not the 
USDA, is the governing agency responsible for the approval of new drugs and their uses 
as well as for setting the allowable levels of drugs in the tissues of food animals. 
However, the USDA recognizes that it must make coordinated efforts to address the issue 
given the urgency of antibiotic resistance.217 With only prior “patchwork” efforts, the 
USDA saw a need to create a strategic vision for its part in the response to slowing 
antibiotic resistance.218 
In 2014, the USDA released an action plan for antimicrobial resistance.219 In the 
plan, the agency argues that even though it has no regulatory authority, it has been at the 
table, partnering with other governmental agencies as well as industry to mitigate 
antimicrobial resistance. The agency released this action plan under the realization that its 
contribution has been limited.  
For nearly two decades, USDA has been actively involved in surveillance, 
basic and applied research, and education and outreach to assess levels of 
AMR [Antimicrobial Resistance], to develop effective mitigation 
strategies. These activities have made important individual agency 
contributions to understanding the role of animal agriculture in AMR and 
to minimizing its selection and spread. However, these efforts lacked 
integration and prioritization at the departmental level. This has ultimately 
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limited their overall impact. USDA recognizes that considerable work 
remains, and there is a growing sense of urgency to address this problem. 
Through this action plan, USDA describes a roadmap for a 
comprehensive, integrated approach to develop effective, practical 
mitigation strategies for animal agriculture to help prolong the 
effectiveness of antibiotics used to treat people and animals.220 
The action plan outlines three objectives that are foundational in the development of 
strategies to slow antimicrobial resistance: 
• Determine and/or model patterns, purposes, and impacts of antibiotic use 
in food-producing animals. 
• Monitor antibiotic drug susceptibilities of selected bacterial organisms in 
food-producing animals, production environments, and meat and poultry. 
• Identify feasible management practices, alternatives to antibiotic use, and 
other mitigations to reduce [antimicrobial resistance] with food-producing 
animals and their production environments.221 
The USDA believes more work is needed to understand the agricultural role in 
antimicrobial resistance. The agency wishes to “address recognized knowledge gaps and 
develop effective, practical mitigation strategies that will help to prolong the 
effectiveness of antibiotics to treat both people and animals.”222 The action plan outlines 
how the agency will gain better information on antibiotic resistance in food animals 
through surveillance, research and development, and education and outreach. The plan 
also outlines a proposal for surveillance and longitudinal studies of volunteer animal 
producers. The studies would collect data on antimicrobial drug use as well as 
information on farming practices through new surveys. The surveillance also requires 
biological sampling of the products at slaughter to test for antimicrobial resistant 
bacteria.223 In addition to the new studies, the plan outlines adding questions about 
antibiotic drug use and farm management practices to existing surveys. These are 
voluntary surveys and the data obtained from them will allow analysts to monitor trends 
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over time. This information could measure the impact of policy implementation and also 
help identify areas where mitigation measures are needed to slow antimicrobial 
resistance.224 
An additional proposal in the USDA plan is to routinely perform antibiotic 
susceptibility testing on animal pathogens that are reported from veterinary diagnostic 
laboratories. The recommendation is to develop a voluntary system that would link all the 
gathered data to help veterinarians select appropriate treatment; it could also provide new 
information about emerging animal health threats and potentially new zoonotic or 
foodborne threats that could affect human health.225  
Further, the USDA believes additional research is needed on microbial ecology in 
relation to several farm management practices, including feeding, administration of 
drugs, physical environment, and transporting animals.226 The agency argues that more 
research is needed to understand the causes behind antimicrobial resistance in food 
animals; however, the action plan is vague regarding how the research should be 
completed. Furthermore, the agency discusses the need to develop new antimicrobials 
and promote the use of alternatives to antibiotics to meet the challenges posed by 
antimicrobial resistance.  
The USDA also recommends partnering with researchers in academia and 
government to advance new technologies and approaches to animal production that do 
not contribute to antimicrobial resistance. The USDA proposes working more closely 
with the CDC on education and outreach surrounding judicious use of antimicrobials. 
Specifically, the plan calls for a reinstitution of the “Get Smart: Know When Antibiotics 
Work on the Farm” campaign, which aimed to reach farmers and veterinarians and was 
recently discontinued.227 The plan also includes a proposal for an online presence that 
provides information about judicious antimicrobial use and summarizes the data gathered 
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from the other proposals. The tool would include best quality assurance practices 
gathered from various agriculture sectors. 
Finally, the plan includes a proposal to make a maximum of $6 million available 
through a competitive request-for-applications process to develop integrated projects to 
address antimicrobial resistance. A few examples provided in the plan are outreach and 
education materials, tools such as websites that meet various target audience needs, and 
new studies that examine the efficacy of research or education and outreach interventions 
related to antimicrobial resistance.228   
It is unclear if the USDA has worked with partners or stakeholders to implement 
any of these strategies. A 2016 audit by its Office of Inspector General found that the 
USDA’s antibiotic resistance goals and objectives are ill-defined, which makes it difficult 
to measure progress or effectiveness of the agency’s efforts.229 The audit includes 
responses to all of the findings and timelines for completion; however, again, it is unclear 
if these activities have continued since the publication of the audit.  
C. SURVEILLANCE SYSTEMS AND DATA COLLECTION 
The United States does not have a comprehensive system—like those in Denmark 
and the Netherlands—to collect good data on antibiotic use or surveillance on resistance 
in animals or humans. This section discusses systems and projects that were initiated by 
federal agencies to measure antibiotic resistance but that are narrow in scope.   
1. USDA National Animal Health Monitoring System (NAHMS): 
Antimicrobial Resistance Studies 
According to the USDA’s webpage on the topic, the National Animals Health 
Monitoring System (NAHMS) was launched in 1983 to collect data on agricultural 
productivity, as well as animal health and management.230 Formal NAHMS studies on 
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the nation’s agricultural sectors did not begin until 1990, after several years of designing 
the program.231 Today, NAHMS develops national data on disease exposure as well as 
incidence.232  
One publication based on NAHMS data, released in July 2009, identifies the 
prevalence of Salmonella and Campylobacter on U.S. dairy farms and compares 
prevalence and resistance between 1996 and 2007, along with susceptibility.233 The 
authors found that the prevalence of Salmonella increased over the three study years—
1996, 2002, and 2007. However, antimicrobial resistance was minimal and did not 
significantly increase over time among Salmonella isolates.234 In addition, 
Campylobacter was prevalent in most of the dairy farms observed in the study. 
Susceptibility testing was conducted on Campylobacter jejuni isolates in 2002 and in 
2007 and showed that there was clear resistance to tetracycline; 47.4 percent of isolates 
were resistant in 2002 and 62.9 percent had become resistant by 2007.235 
A more recent publication, released in April 2016, describes a 2012 NAHMS 
study on 2,119 randomly selected swine farms in thirteen states.236 The aim of the study 
was to identify the extent to which food animals, pigs in particular, carry resistant genes 
that could be transferred to humans. The researchers conducted two interviews on each 
site and collected biological specimens on some of the sites. E. coli was found on all of 
the sites, which is not surprising—E. coli is one of the many organisms that normally live 
in food animals. However, the researchers found that 92.8 percent of the E.coli from the 
specimens was resistant to at least one antimicrobial, with 91.2 percent resistant to 
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tetracycline alone. There was low resistance to ciprofloxacin, 0.4 percent of isolates, and 
1.6 percent of isolates were resistant to amoxicillin.237 
Two additional antimicrobial use studies are currently listed on the program’s 
website: the “NAHMS Antimicrobial Use on U.S. Feedlots, 2017 Study” and the 
“NAHMS Antimicrobial Use on U.S. Swine Operations, 2017 Study.” They were both 
scheduled to be conducted from May through August of 2017.238 The aim of the studies 
is to review the use of antimicrobials on feedlots containing at least fifty animals and to 
examine antimicrobial use on U.S. swine farms containing at least 1,000 animals.239 
Both projects are new fields of study to be conducted every other year.240 These studies 
are outcomes of the USDA’s Antimicrobial Resistance Action Plan and the projects will 
provide baseline data on antimicrobial use practices that existed prior to the feed changes 
the FDA implemented, as the information gathered is about antimicrobial use during 
2016.241 To conduct each study, USDA veterinarians were slated to interview feedlot 
operators who volunteered to participate in the study. The data collection phase for each 
project concluded in August 2017. As of the publication of this thesis, study results for 
both projects have not been published.  
2. National Antimicrobial Resistance Monitoring System (NARMS) 
Established in 1996 by the FDA, NARMS is a national surveillance system that 
tracks antibiotic susceptibility of enteric bacteria.242 The program, which collects data on 
humans, animals, and retail meats, is a partnership between the FDA, USDA, and CDC to 
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monitor resistance among these specific foodborne bacteria: Salmonella, Escherichia 
coli, Campylobacter, and Enterococcus.243 The program performs whole-genome 
sequencing to analyze these bacteria by serotyping and speciation, which will contribute 
to the understanding of how resistant organisms can be distributed in the food chain.244  
NARMS publishes annual data on its website. There are several dashboards on 
the site that allow users to view resistance by species and serotype or by sample source 
and place, resistance genes in Salmonella, multidrug resistance by antimicrobial agents, 
and multidrug resistance by the number of antimicrobial classes.245 In addition, visitors 
can download data on human clinical cases, retail meats, and animals. Another interactive 
online tool, NARMS Now: Human Data, which is hosted by the CDC, shows data on 
resistant bacteria that have been isolated from humans. On the site, the user can select the 
bacteria and serotype, the antibiotic, and a timeframe. Then, the user can select how the 
tool will display the resistance information by year and by state. It can be displayed as a 
map of the United States, with states shaded different colors depending on the percentage 
of isolates that are resistant, or it can be displayed in a table. Nationwide resistance can 
also be displayed by year in a graph or table.246  
D. CONCLUSION 
Reviewing the United States’ efforts as a national package, the strategies certainly 
do not go as far as other countries’ have. Perhaps the way policy decisions are discussed 
in European countries might explain the difference. On this issue in particular, the 
rationale for the European Union banning the use of antimicrobial growth promoters was 
based on the precautionary principle: “a precautionary measure to minimize the risk of 
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development of resistant bacteria and to preserve the efficacy of certain antibiotics used 
in human medicine.”247 This principle is not widely accepted in the United States for 
regulatory policymaking.248 
Even though evidence links antibiotic use to antibiotic resistance, the industry 
purports that there is no proof linking the use of antibiotics in agriculture to drug-resistant 
infections in humans. Presumably because of industry pushback, U.S. strategies have not 
been implemented, and many of the regulations are voluntary. The ban of the off-label 
uses of cephalosporins is a positive step toward using fewer medically important drugs 
for humans in agriculture; however, this is likely not enough to make meaningful change. 
Another successful strategy appears to be the “Guidance for Industry #213” document. 
Again, however, this was a voluntary measure to transition medically important 
antimicrobials used in feed or water from over-the-counter status to prescription status, 
and to prohibit the use of medically important antimicrobials for growth promotion.249  
The FDA issued a press release on January 3, 2017, with an update on the 
implementation.250 In the release, the agency commends the pharmaceutical industry for 
working with the FDA to align its products with the recommended guidance.251 All 
thirty-one drug applications that indicated use of antimicrobial products for growth 
promotion were withdrawn or re-labeled without that particular use listed, meaning 
antimicrobials can no longer legally be used as growth promoters in the United States.252 
In addition, there were 292 drug applications that fell into the category of medically 
important antimicrobials fitting the criteria to transition to prescription or veterinary feed 
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directive status.253 Of those applications, 93 were converted from over-the-counter to 
prescription, and 115 products were converted to veterinary feed directive status.254 This 
means all medically important antimicrobials being used in animal production have been 
modified to require veterinary oversight in some way.  
What effect will this have on industry? It difficult to know—and it is unclear if 
the FDA has plans in place to evaluate these policies and their effects on the agriculture, 
veterinary, and pharmaceutical industries in the future. That said, in an interview with the 
Wall Street Journal in 2013, the chief executive of Zoetis, an animal health company 
formerly part of Pfizer, went on record saying that the FDA approach of eliminating 
growth-promotion indication from the label on feed “will not have a significant impact on 
our revenues.”255  
What effect will this have on slowing the threat? The federal government may 
find it very difficult to measure. The United States has a limited set of data for 
comparision. The monitoring systems in place are specific to foodborne illness, sales 
data, or special studies conducted on an ad hoc basis. Based on the experiences of the 
other countries studied in this thesis, the United States may not see any declines in the 
use of antibiotics. There were no targets set for reducing overall use, nor were there 
regulations or strong guidance addressing the routine use of antimicrobials as disease 
prevention; will farmers continue to use medically important drugs as tools for disease 
prevention to achieve the same outcomes? Without a comprehensive data collection 
system, it will be impossible to monitor trends. The U.S. government will need to 
continue to rely on the antimicrobial sales data that it has used for decades.  
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V. CASE STUDY: UNITED STATES 
In the absence of national requirements, states are exploring legislation with the 
aim of preserving antimicrobials. California has enacted legislation that is based largely 
on antibiotic bans in Europe. It is interesting to note that California, the top agriculture-
producing state in the nation in 2016, was able to pass such legislation.256 Only seven 
legislators voted against the bill, which suggests that producers were not opposed.257 
While this bill may not be a true indicator of support for a national ban, it does offer 
evidence that such legislation may pass in other agriculture states. Maryland, however, a 
much smaller producer, proposed similar standards that were ultimately not adopted due 
to pressures from the farm lobby.  
While this chapter only examines California’s and Maryland’s policies, a 2017 
tracking project from the Association of State and Territorial Health Officials shows that 
several states have proposed legislation aimed at slowing antibiotic resistance. Only 
Maryland and Oregon proposed laws related to antimicrobials in the agriculture industry. 
Arkansas and Texas also proposed legislation, but the bills focus on the human health-
care industry. While it is possible that other states may be exploring legislation, the 
position of most states is not known.  
A. CALIFORNIA  
In the absence of federal policy, California has sought state-level legislation to 
slow the threat of antibiotic resistance. California is the first state in the nation to 
implement a law limiting the use of antibiotics in livestock.  
1. Legislative Ban 
California Governor Jerry Brown signed legislation on October 10, 2015, banning 
the use of medically important antimicrobials as growth promoters or as a means to 
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improve feed efficiency. According to a justification provided in a budget change request, 
the law was proposed to address the public health implications of use and overuse of 
antibiotics in livestock, which contributes to antibiotic resistance.258 Under this law, 
“medically important drugs” are considered those used by humans and that are necessary 
to treat or control the spread of disease, as well as those necessary for surgery and 
medical procedures.259 The bill prohibits the administration of medically important 
antimicrobial drugs “in a regular pattern” and states that the drugs can only be used under 
a prescription or veterinary feed directive through a veterinarian.260  
The legislation also includes penalties for violations to the law, including $250 
per-day fines and $500 per day for second violations. Violators are required to attend and 
complete an educational program on the judicious use of medically important 
antimicrobials within ninety days of the violation. Veterinarians who do not comply with 
the law as determined by the Veterinary Medical Board are subject to disciplinary 
sanctions under the Veterinary Medicine Practice Act.261  
2. Antimicrobial Dispensing
Under California’s legislative ban, farmers and veterinarians must establish a 
“veterinarian-client-patient relationship,” or VCPR. VCPRs are considered valid once a 
veterinarian examines the livestock or visits the farm when medically necessary.262 The 
vet must be knowledgeable enough about the animals to diagnose medical conditions. 
When making medical judgements regarding the health of animals, the veterinarian must 
communicate with the farmer about the appropriate course of treatment and cannot 
prescribe drugs for a duration that is inconsistent with the medical or drug type. In 
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addition, veterinarians can only prescribe drugs for use within twelve months of the last 
examination—meaning veterinarians cannot issue a script for potential future problems 
without an examination.263 To maintain a license, veterinarians must also “complete a 
minimum of one credit hour of continuing education on the judicious use of medically 
important antimicrobial drugs every four years as part of his or her continuing education 
requirements.”264 To meet this requirement, vets may complete the United States 
Department of Agriculture’s training program called Module 23: Use of Antibiotics in 
Animals. 
Medically important antimicrobial drugs can only be sold by licensed retailers 
with a prescription or with a veterinary feed directive from a licensed vet. This restriction 
includes drugs that had previously been sold over the counter. As of January 1, 2018, 
additional regulations have been published that clarify which retail establishments are 
required to have a restricted livestock drug license in order to sell medically important 
antimicrobial drugs; the regulations also clarify requirements for record keeping, drug 
storage, and drug labeling.265  
Furthermore, the law charges the California Department of Food and Agriculture 
to work with stakeholders to develop “antimicrobial stewardship guidelines and best 
management practices for veterinarians, as well as livestock owners and their employees 
who are involved with administering medically important antimicrobial drugs.”266 This 
guidance must include alternatives to the use of medically important antimicrobials such 
as vaccination, good hygiene, and farm management practices.267 The bill defines 
“antimicrobial stewardship” as a commitment to 
use medically important antimicrobial drugs only when necessary to treat, 
control, and, in some cases, prevent disease, to select the appropriate 
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medically important antimicrobial drug and the appropriate dose, duration 
and rout of administration; and to use medically important antimicrobial 
drugs for the shortest duration necessary and to administer them to the 
fewest animals necessary.268  
3. Monitoring Antibiotic Use and Resistance 
California’s legislation also requires the state’s Department of Food and 
Agriculture to begin a monitoring program that will gather information on the sale and 
use of antibiotics, along with information on antibiotic-resistant bacteria and livestock 
management practices. The department is required to work with the USDA, FDA, and 
CDC to enhance national surveillance efforts. The department must also collect 
regionally representative information from all of California’s major livestock sectors and 
segments of the food production chain and ensure confidentiality within the monitoring 
system.  
4. Implementation 
The California Department of Food and Agriculture created a strategic plan for its 
two-year implementation period (2016–2017). In terms of the regulated-use component 
of this legislation, the implementation activities focused on administrative rule 
development and outreach activities to achieve compliance goals. The department has 
reviewed the statutory language to identify gaps in existing and new regulations. The goal 
was to finalize all regulations before 2018 and it appears all regulations have been 
published as of the writing of this thesis. The estimated total cost to implement the 
regulations is $4 million, which includes $1.393 million in California state tax dollars and 
an additional eight positions to be added to the California Department of Food and 
Agriculture.269  
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In terms of outreach activities, the department has developed materials such as 
brochures, completed scores of presentations, and developed a web and social media 
presence.270 As of November 27, 2017, the department had visited approximately 340 
retailers to further educate them on the upcoming law changes; this ensured that both 
licensed and unlicensed retailers were aware that medically important drugs are only to 
be sold under a veterinary feed directive or prescription.271 Another objective of the 
strategic plan is to gather baseline compliance data from industry partners to develop a 
point of reference when evaluating future compliance. As of October 2018, the 
department had visited feed mills, distributors, and other facilities to provide outreach 
and education on the laws.272 The department also provided technical assistance and 
advice regarding any changes feed mills needed to make with their veterinary feed 
directives to be in compliance with the new law.273  
What is remarkable about this legislation is that California had a great window of 
opportunity to enact it. The environment evolved over many years, which allowed for 
discussion and collaboration. Interestingly, the majority of the opposition did not 
surround typical arguments that have been made at the national level; instead, the 
industry partners who provided comments or testified on early versions of the bill argued 
that the proposed legislation did not go far enough.274 Most of the industry partners 
remained neutral on the bill and only seven lawmakers did not vote in favor of it.275  
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5. Potential Impacts on Industry 
As stated previously, the majority of the industry partners remain neutral on the 
bill for varying reasons. In an interview with KQED News, a representative from the 
Farm Bureau commented, “We have members who are not able to use antibiotics that 
they used to, so we recognize the importance of being engaged in the discussion of 
having antibiotics available and effective in the future.”276 However, the Farm Bureau 
did not fully support the bill because it requires a veterinarian prescription for antibiotics, 
and rural producers may not have consistent access to veterinarians.277 Another article, 
published by Vox, suggests that farmers have been opposed to broad restrictions because 
of the nuances in determining therapeutic use versus nontherapeutic use.278 
Pharmaceutical and agriculture lobbyists have argued that antimicrobial regulation could 
raise costs for farmers. The California Cattlemen’s Association voiced its concerns about 
prohibiting over-the-counter antibiotics as well as the potential burden created by 
requirements to report on farm antimicrobial use.279  
Veterinarians who testified at an April 2015 hearing on the bill, and in a letter to 
the bill’s author, addressed the accessibility concerns from the food producers, stating, 
“The veterinarian-client relationship is very flexible in terms of how the veterinarian can 
best serve the client. In fact, a veterinarian may write a prescription for up to one year 
and develop a protocol for the client to administer the drug in his or her absence.”280 In 
the same letter, the California Veterinary Medical Association also shared concerns about 
the burden of reporting antibiotic use and uncertainty around whether reporting would be 
a breach of the veterinary medicine confidentiality statute. The Agriculture Council of 
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California also cited confidentiality concerns on its website when the bill was first 
introduced.281 These issues are all examples of potential impacts that may make the 
industry hesitant to embrace this legislation and could potentially be examined when or if 
the California government performs an evaluation on its policy. 
6. Assessment
By January 1, 2019, the Department of Food and Agriculture must submit a report 
to the state legislature outlining its monitoring efforts. The department must determine 
whether enough of the industry is on board to measure if the law is in fact moving the 
needle on non-therapeutic antimicrobial use and resistant organisms.282 The complete 
assessment of this law can only be made after several years of data gathering and 
observation of trends. It therefore remains to be seen if the California legislation, as 
enacted, will have an impact on the rates of antibiotic resistance. However, through the 
monitoring and surveillance report, the Department of Food and Agriculture should have 
the information it will need to evaluate the effects of this law. The department should also 
look to evaluate the potential impacts on industry mentioned in the previous section.  
B. MARYLAND 
Maryland has also enacted legislation aimed at slowing the threat of antibiotic 
resistance. This section discusses the state’s policy approach and the opposition it has 
encountered.  
1. Legislative Ban
Maryland became the second state in the nation to pass legislation limiting routine 
antibiotic use in certain food animals.283 The law, effective January 1, 2018, only allows 
the use of medically important antimicrobial drugs in poultry, pigs, or cattle if a 
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veterinarian determines that it is necessary to treat or control disease or for a medical 
procedure. Medically important antimicrobial drugs cannot be used in a “regular 
pattern.”284 The regulations do not apply to cattle or swine farms selling less than 200 
animals per year or poultry operations that sell less than 60,000 birds per year. Under the 
law, the secretary of the Maryland Department of Agriculture has the authority under the 
law to impose penalties up to $2,000 for violations of the regulations. The law also 
prohibits medically important antimicrobial drugs used for growth promotion, feed 
efficiency, or weight gain purposes.285 
2. Antimicrobial Dispensing 
Under the passed legislation, prophylactic use of antibiotics is only allowed after 
a veterinarian determines that an event has caused a significant disease risk to the 
herd.286 However, earlier versions of the bill stated that the producer and veterinarian 
must have an established veterinarian-client-patient relationship as defined by federal 
code.287 In addition, earlier versions proposed requiring that these drugs are administered 
to the fewest number of animals possible for the shortest amount of time as stated by the 
prescription or veterinary feed directive, much like the California legislation. These 
provisions were struck from the final bill.  
3. Monitoring Antibiotic Use and Resistance 
The legislation requires the Maryland Department of Agriculture to report state-
level data from the USDA, CDC, FDA, and any other appropriate national trade 
associations, organizations, and councils to the Maryland General Assembly. The 
reporting must happen each year on December 1, beginning in 2019.288 Earlier versions 
of the bill proposed that veterinarians and/or farm owners annually submit copies of 
medically important antimicrobial prescriptions as well as copies of veterinary feed 
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directives issued during the previous calendar year to the Maryland Department of 
Agriculture.289 The department would have been required to provide a report detailing all 
the information to the General Assembly each December.290 
4. Opposition 
According to news reports, the original version of the bill, which prohibited the 
use of antibiotics as prophylaxis without a prescription or veterinary feed directive, faced 
opposition. The bill had also required farmers to submit those prescriptions or directives 
to the Maryland Department of Agriculture—a measure that was deemed by some to be 
too onerous.291 In addition, the Maryland Farm Bureau opposed the bill because it was 
considered duplicative to regulations at the federal level; however, the bureau president 
also stated that the policies would cause more outbreaks that would require antibiotics, 
which would cause resistance.292 Industry representatives indicated that these measures 
were unnecessary because the public was already demanding antibiotic-free poultry and 
the industry is “pretty much headed in that direction, anyway.”293 Media accounts also 
report opposition to the bill—which took three years to pass—from the pharmaceutical 
industry.294  
Not all industry members were opposed, however. An opinion piece in the 
Frederick News-Post written by a Maryland farmer challenged the industry’s opposition 
to the legislation.295 He acknowledged the use of medically important drugs by industry 
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as disease prevention—even if it is unwarranted—and urged fellow farmers to engage in 
conversations with one another about how best practices in farm management can be 
achieved.296  
Furthermore, not all opposition came directly from industry. In fact, the Maryland 
Department of Agriculture registered written opposition to the act in February 2017.297 
The department’s rationale was similar to industry; it was considered “duplicative and 
incomplete compared to the national effort by the FDA.”298 The department also 
submitted that the bill, as written, would “cause an unnecessary operational and fiscal 
impact on the Department.”299 The estimated costs to implement this legislation were 
between $185,000 and $262,000. The agency said additional resources would be needed 
to manage the regulatory components of the bill, and opposed the bill because it did not 
have the same authority that the federal government has to enforce its provisions. The 
department also opposed the provision prohibiting the use of medically important 
antibiotics for routine disease prevention. The agency considered it “confusing” and 
believed it should be “stricken from [the bill] as one of the conditions where medically 
important antimicrobials may not be administered.”300  
5. Implementation 
Under the law, the Maryland Department of Agriculture is allowed to adopt 
regulations to carry out the legislation.301 It does not appear that much will need to be 
implemented by any entity, which is somewhat puzzling. According to a blog sponsored 
by the University of Maryland College of Agriculture and Natural Resources, the act is 
very similar to the FDA’s veterinary feed directive rule, thereby making it redundant to 
                                                 
296 Smith. 
297 “Maryland Department of Agriculture Legislative Comment—Keep Antibiotics Effective Act of 
2017,” Maryland Department of Agriculture, February 15, 2017, http://mda.maryland.gov/about_mda/ 
Documents/2017-HB602-SB422-Antibiotics.pdf. 
298 Maryland Department of Agriculture. 
299 Maryland Department of Agriculture. 
300 Maryland Department of Agriculture. 
301 Keep Antibiotics Effective Act. 
71 
the initiatives being undertaken at the federal level.302 It is unclear what this legislation, 
as passed, will accomplish. 
6. Potential Impacts on Industry 
It is difficult to piece together precisely what led to the amendments that resulted 
in the passage of the final bill, but the legislation was significantly stripped down from its 
initial version, possibly due to the opposition. There will likely be limited effects to 
industry given that federal rules have already addressed the concerns this legislation 
targets. Perhaps the main impact to industry would be penalties for violators; however, 
the penalty does not exceed $2,000. The law does not explain if multiple penalties can be 
accrued, or who—a veterinarian or a farmer, or some other individual—may violate the 
provisions. In addition, given that there is no state-level data collection effort, it remains 
to be seen how the effectiveness of this law will be evaluated.  
7. Assessment 
Because Maryland’s law is redundant with FDA guidance and does not alter 
veterinarian involvement in food-animal production, nor does it require new data 
collection or surveillance, this legislation does not appear to contribute to knowledge or 
understanding of antibiotic use in animal husbandry in the state, nor does it set reduction 
goals for the use of medically important antimicrobials. It is unclear if the current law 
will have an impact on antibiotic use in Maryland—although it will be difficult to 
measure.  
C. CONCLUSION 
This chapter examined the two U.S. states that have, at the time of this writing, 
passed legislation to slow the threat of antibiotic resistance. California’s law, the only law 
in the nation that requires a prescription by a veterinarian to use antibiotics in livestock, 
bans non-therapeutic uses and requires data to be collected on antibiotic use in food 
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animals. Maryland’s legislation essentially codifies FDA guidance by banning the use of 
medically important drugs for growth promotion or feed efficiency, but also assigns 
penalties for violations. Maryland, unlike California, received opposition from the farm 
lobby, possibly resulting in the stripped-down version of the legislation that was adopted. 
Even though these states’ laws are different and were passed with varying levels of 
opposition, it is clear there is some commitment to regulation on antibiotic use.  
The chapters that follow compare the policies that have been implemented in each 
of the case studies examined, provide an evaluation of various policy options that the 
United States could consider implementing, and recommend a way forward for the 
homeland security enterprise to help slow the threat of antibiotic resistance.  
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VI. CASE STUDY POLICY COMPARISONS 
The case studies and current U.S. strategies presented in the previous chapters can 
be analyzed to determine if legal policies have led to a decline in antibiotic resistance in 
animals or people. This chapter compares three policy strategies among the case studies: 
legislative bans, antimicrobial dispensing, and monitoring. Each section includes tables 
that display different policy actions taken in the previously discussed countries. The 
Appendix contains a matrix summarizing the major policy actions for each case study. 
A. LEGISLATIVE BANS 
All the countries and states studied—with the exception of the United States at the 
national level—implemented a legislative or regulatory ban on the use of antibiotics as 
growth promoters. This section compares the types of uses that were banned and 
discusses whether there are penalties associated with violations. Table 1 displays the 
types of nontherapeutic uses banned—production and prevention—and if the ban was 
implemented for medically important antimicrobials only. Bans for production purposes 
include growth promotion and feed efficiency; banning routine disease prevention 
includes using antimicrobials without evidence of disease.  
Table 1. Nontherapeutic Uses Banned 

















Denmark Yes No Yes No  
Netherlands Yes No No N/A 
California Yes Yes No N/A 
Maryland Yes Yes No Yes 
United States, 
national 
No – however, all 
manufacturers have 
voluntarily complied 
with FDA guidance 
to ban the use  
Yes No N/A 
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The United States’ approach to antibiotic use as a growth promoter has been 
specific to the definition of medically important antimicrobials, or those drugs that are 
important for human medicine; the European countries studied, however, banned the use 
of all antimicrobials for growth promotion. The state-level regulations in the United 
States prohibit the administration of medically important antimicrobials “in a regular 
pattern,” which means they should only be used to treat disease, to control the spread of 
disease, or for medical procedures.303 These regulations—along with national-level U.S. 
law—allow veterinarians to prescribe medically important antimicrobials if they are 
situationally needed to prevent disease. For example, the FDA describes the following 
scenario of acceptable use: “If a veterinarian determines, based on a client’s production 
practices and herd health history, that cattle being transported or otherwise stressed are 
more likely to develop a certain bacterial infection, preventively treating these cattle with 
an antimicrobial approved for prevention of that bacterial infection would be considered a 
judicious use.”304 However, the guidance indicates that use of medically important drugs 
in healthy animals without evidence of risk of disease is not judicious use.305 For 
purposes of this thesis, the United States allows use without evidence of disease; it 
therefore considers the United States to allow (rather than ban) antimicrobials for 
preventative purposes.  
Even though it is voluntary for producers to stop using antibiotics for growth 
promotion in the United States, the pharmaceutical industry has responded by changing 
labels on medically important antibiotics to ensure that growth promotion use is 
discouraged. In addition, the FDA has restricted the use of some medically important 
antimicrobials in animals, as outlined in Table 2.  
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Table 2. Drug Classes Banned or Limited for Use in Food Animals 
 Drug Class 
Fluoroquinolones Cephalosporins Glycopeptides 
Denmark Yes – limited use  Yes – limited use Yes – Avoparcin 
Netherlands Yes – 3rd and 4th 
generation 
Yes – 3rd and 4th 
generation 
Yes – Avoparcin 
California No additional limits No additional limits No additional limits 




Yes – extra label use 
prohibited, and 
prohibited in poultry 
Yes – extra label use of 3rd 
and 4th generation 
prohibited 
Yes – none have been 
approved for use in 
food animals 
 
Denmark banned the use of avoparcin for growth promotion in 1995 out of 
concerns that it was contributing to the resistance of vancomycin—a drug used to treat 
human infections.306 Avoparcin and vancomycin are chemically very similar 
antibiotics.307 Given that avoparcin was never approved for use in the United States, it is 
somewhat out of scope for this analysis; it is worth mentioning, however, because this 
was the first step in banning or limiting antibiotic use in agriculture settings.308 The 
United States, Denmark, and the Netherlands have all limited or restricted the use of 
fluoroquinolones in some manner, and the Netherlands and the United States have limited 
the use of third- and fourth-generation cephalosporins. Denmark has prohibited the use of 
cephalosporins in poultry.309 The Netherlands created a tiered system that outlines which 
drugs should be used first, second, or third for treatment in order to preserve the most 
important antibiotics for human consumption and limit the likelihood of resistance. No 
other countries studied in this thesis have this type of ranking system. 
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Table 3 presents a comparison of penalties outlined in the countries’ and states’ 
policies. The California and Maryland laws impose monetary penalties for producers who 
violate their provisions. California’s penalties are up to $500 per day until the producer 
becomes compliant with the law while Maryland’s penalties do not exceed $2,000.310 
Denmark instituted its yellow card initiative, which set targets for antibiotic use; 
producers who exceed the threshold limits are given yellow cards and are fined. While 
the SDa in the Netherlands sets antibiotic-use reduction targets for each food-animal 
species, there is no penalty for failing to meet targets. Instead, producers who use too 
many antibiotics receive technical assistance on how to reduce their use.311 
Table 3. Penalties 
 Penalties imposed Penalty type 
Denmark Yes Fines if antibiotic use thresholds are not met; costs for 
inspection visit; for a third injunction, stock reduction 
is an option 
Netherlands No Guidance provided to producers who use too many 
antibiotics312 
California Yes Fines of up to $500 per day until compliance 
Maryland Yes Fines not to exceed $2,000 imposed by the secretary 






Because the policies are voluntary in the United States, no specific penalties are 
outlined in the guidance for veterinarians and producers who use antibiotics in an off-
label fashion. It appears that there are conditions where extra-label drug use is allowable 
and record keeping must be accurate and comprehensive. The guidance states that 
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continued use of antimicrobials for production purposes is an “illegal extra-label use”; 
however, it is unclear what the penalties are, if there are any to begin with, for violating 
the law.313  
B. ANTIMICROBIAL DISPENSING 
All the countries and states studied impose some limits on the use of 
antimicrobials and how they are dispensed. Table 4 presents requirements in each of the 
policies outlining whether or not a veterinary visit is required to use antibiotics, if a 
prescription is required to administer antibiotics, if a veterinarian-client relationship is 
required, and whether or not there are additional educational or certification requirements 
veterinarians must meet to provide antibiotics. 
Table 4. Veterinary Requirements 
 Veterinary visit 












Denmark Yes – monthly visits 
for swine and cattle 
producers  
Yes No No 
Netherlands Yes – prior to 
prescribing to sick 
animals, and periodic 
visits 
Yes Yes Yes – in order to 
be listed in the 
veterinary quality 
register  
California Yes – yearly visit 
required 




Maryland No Yes – medically 
important drugs 
only 







No Yes – medically 
important drugs 
only 
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1. Veterinary Oversight 
A prescription is required for antibiotics in all the countries; however, in the 
United States this requirement is only for drugs that are deemed medically important to 
human medicine. The European countries require all antibiotics used in food animals to 
be dispensed through a veterinary prescription. Denmark additionally requires monthly 
visits from veterinarians to larger swine and cattle producers so the vets may advise on 
drug use and other animal health concerns.314 The Netherlands mandates a vet visit 
before antibiotics can be prescribed to treat ill animals.315 As far as dispensing policies, 
Denmark legislation does not allow veterinarians to profit from antibiotic sales and the 
government prohibited veterinary dispensing in 1990; all distribution is done through 
pharmacies.316 However, Dutch officials do not believe that decoupling the prescription 
and sale of drugs will result in decreased antibiotic use.317 The Dutch rely on their use 
targets to remove economic incentives from antimicrobial prescriptions and sales.318  
The California and Dutch policies are similar in that they both require a 
relationship with a veterinarian. The Netherlands policy specifies that producers can only 
contract with one veterinary practice whereas California only requires that veterinarian-
client-patient relationships must be established for each farm. These two models also 
require veterinarians to visit farms before antibiotics can be prescribed to ill animals; 
however, the California model further requires a yearly visit to the farm from a 
veterinarian with an established relationship before antibiotics can be prescribed at all.  
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2. The Dutch Quality System 
Another aspect unique to the Netherlands model is the creation of a quality 
system for veterinarians. The system includes clinical treatment guidelines for 
veterinarians that can be enforced through private quality systems in place in the 
country.319 Veterinarians who are abiding by these guidelines are listed in the country’s 
registers as approved veterinarians, thereby pressuring veterinarians to follow the 
guidelines. Producers will know who the high-quality veterinarians are in the country and 
seek out their services. None of the other countries studied have this type of quality 
program for veterinarians. Also unlike the other countries, the Dutch quality system 
requires those who wish to be listed in the registry to pursue accredited continuing 
education courses aimed at reducing antibiotic use in agriculture.  
3. Prescribing Limits 
Denmark allows veterinarians to prescribe or distribute antibiotics for treatment to 
animals, with the exception of cattle, for a maximum of five days. No other policies 
examined had specific limits regarding the number of days antibiotics may be used for 
treatment. California’s policy prohibits the prescription of drugs for a duration that is 
inconsistent with treatment guidelines for either the disease or the drug type.  
C. MONITORING 
This section compares the various monitoring requirements for each of the 
countries and states, including the individuals who are required to provide information. 
All the policies include some surveillance component to monitor the antibiotic resistance 
threat. The European countries’ systems are integrated, nationwide systems that collect 
information on antibiotic use and resistance in human health and in agriculture, whereas 
the United States has disconnected monitoring systems that are limited in scope. In 
addition, the U.S. systems do not record antibiotic use. Table 5 outlines which countries 
and states measure antibiotic use, resistance levels in food, resistant infections in animals, 
and resistant infections in people.   
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Denmark Yes Yes Yes Yes Yes 

















Maryland Yes – same 
as national 
level 




Yes – limited 
to antibiotic 












Denmark’s DANMAP is an integrated system that monitors the use of 
antimicrobial drugs in food animals and in people, resistance levels in food, and whether 
or not resistant infections are increasing in animals and in people. Similarly, in the 
Netherlands, the SDa releases summaries on antimicrobial use in animals and people, as 
well as resistance levels in food and resistant infections in humans and animals. The 
Netherlands, unlike Denmark, sets benchmarks on the human side as well as the animal 
side for reducing antibiotic use.  
The United States’ approach is somewhat fragmented compared to the European 
countries discussed. It has three disparate systems that serve specific purposes, some of 
which are not solely intended for monitoring antibiotic use or resistance. The FDA keeps 
data on the sale and distribution of antibiotics, which is published in an annual calendar 
year summary of sales and distribution data for drugs approved for use in food-producing 
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animals. These data do not include information on antibiotic use, which is an important 
distinction from the European policies. That said, the annual report is fairly detailed with 
regard to multi-year trends of sales and distribution information and provides data that 
indicate how many medically important antimicrobials are purchased with the intent to 
use—even though the FDA clearly states that “sales and distribution information does not 
represent actual use of the products” in its key points from the 2016 report.320  
The USDA has sporadically conducted studies on antibiotic use in domestic 
livestock and poultry populations through NAHMS (the National Animal Health 
Monitoring System). The unit in charge of this system has also published info sheets on 
the sporadic antibiotic susceptibility studies performed. This system does provide some 
information about antibiotic resistance on the country’s farms. These studies, however, 
serve as snapshots of a point in time and are not set up with the frequency or continuity 
needed to monitor trends. Another U.S. system, one that is specific to antimicrobial 
resistance, is NARMS, the National Antimicrobial Resistance Monitoring System. This 
system collects data specifically on foodborne bacteria from humans, retail meat, 
slaughtering facilities, sick animals, and healthy animals on farms.321 The intent of the 
system is to promote informed decision-making by providing the FDA, USDA, and CDC 
with data on antimicrobial resistance.  
As for the state-level approaches, California’s policy requires the state’s 
Department of Agriculture to enhance surveillance efforts beyond those conducted at the 
national level. The department will be collecting additional data that are regionally 
representative of the state and will seek to create its own surveillance system, which will 
align and possibly feed into the national systems.322 Maryland’s approach is to provide 
an annual summary of state-level data on medically important antibiotic use that is 
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already compiled and made publicly available by the CDC, USDA, and FDA. The state is 
not planning to provide surveillance enhancements beyond the national level.  
When it comes to who must submit data on antibiotic use to the government for 
antimicrobial surveillance systems, the countries and states differ, as shown in Table 6. 
The European countries require certain sectors to report antibiotic use data. In Denmark 
the onus is on the veterinarians, feed mills, and distributors to report any data they have 
regarding antibiotic use on farms; the producer is not required to report. Dutch policy 
requires farmers to report which drugs are administered and veterinarians to report what 
they have prescribed. As of the writing of this thesis, California’s surveillance system is 
not yet operational; it appears, however, that the state will take a voluntary approach to 
gather a representative sample of farmers and veterinarians who wish to participate and 
provide their antibiotic use information.323 Because Maryland relies on national data, 
there are no required reporters as part of its policies and the United States does not collect 
antibiotic use data. 
Table 6. Sectors Required to Submit Data on Antibiotic Use 
 Veterinarians  Farmers  Feed mills  Pharmacies/distributors  
Denmark Yes No Yes Yes 
Netherlands Yes Yes No No 
California No No No No 




N/A N/A N/A N/A 
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This section compares the outcomes of the case studies. Because the U.S. policies 
are still being implemented, little is known about their eventual outcomes. For the 
European countries, Table 7 describes whether the policies have caused an overall 
reduction in antibiotic use, antimicrobial resistance in animals, and antimicrobial-
resistant infections in people.  
Table 7. Reduction in Antibiotic Use 
 Overall reduction in 
antibiotic use 
Overall reduction in 
antimicrobial resistance in 
animals 
Overall reduction in 
antimicrobial-resistant 
infections in people 
Denmark Yes – use targets met 




Netherlands Yes Yes Yes 
California Unknown Unknown Unknown 




Unknown Unknown Unknown 
 
Both Denmark and the Netherlands saw reductions in antibiotic use as well as 
reduced resistance in animals. Denmark only achieved success after it instituted its 
yellow card initiative, which strengthened monitoring agencies’ ability to hold producers 
accountable to the regulations. In addition, studies from Denmark show reduced 
resistance in animals, yet resistant infections in people continue to increase. Their 
surveillance noted that resistance was higher among meat that was imported and for 
people who had acquired their infections outside the country. Similarly, setting 
benchmarks has allowed the Netherlands to witness declines in its antimicrobial sales and 
usage.324 The Netherlands has also seen declines in resistant organisms in livestock.325 
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The Dutch have observed stable rates, and in some cases reductions, of resistant 
infections in people as a result of their policies.326  
Because the California legislation has only recently been implemented, there are 
not yet measurable outcomes. Similarly, the U.S. guidance and subsequent voluntary re-
labeling by drug manufacturers has recently been implemented. It is also unclear how the 
FDA is measuring effectiveness; though the agency has made changes to its annual 
summary report on antibiotic sales, the 2017 report was not released until December 
2018.327 This report was slated to include metrics that would indicate whether the 
guidance made an impact. Because Maryland’s legislation is duplicative of national 
efforts, it is unlikely that these policies would have distinct outcomes; the FDA’s 
summary report also does not include state-level information on antibiotic use.  
E. IMPACTS ON INDUSTRY 
The impacts on industry for the European countries appear to be minimal, and in 
some cases have increased productivity in certain livestock sectors. For example, after 
Denmark initially saw some negative effects for swine after their ban on antibiotics as 
growth promoters, the country was able to reduce its antibiotic use in swine while 
improving productivity, and without affecting mortality rate.328 The Dutch policies also 
appeared not to impact industry; according to the Dutch Minister of Agriculture in June 
2014, the country had decreased use and remained second in agricultural exports.329  
It remains to be seen what the impacts on industry will be for producers in the 
United States as a result of the drug labeling changes. If medically important drugs 
cannot be used for growth promotion but can still be used preventively, it is unclear how 
farmers and the pharmaceutical industry will be affected. Because California’s policies 
are more restrictive, the state serves as a case study to observe as time passes. For 
example, will the veterinary-client relationship requirement put stress on the veterinary 
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industry? Will producers suffer losses like Denmark’s if they are not allowed to use a 
medically important antimicrobial drug in a regular pattern? Future research will be 
needed to assess the impacts of these policies in the United States.  
F. CONCLUSION 
This chapter summarized and compared various policy aspects and outcomes for 
the case studies examined in this thesis. The following broad themes from this emerged. 
• Growth promotion bans: The European countries banned all antibiotics for 
growth promotion rather than just those antibiotics with medical 
importance to humans.  
• Prevention bans: Only Denmark banned the use of antibiotics for routine 
disease prevention without evidence of disease.  
• Drug class bans: All countries have banned flouroquinolones, 
cephalosporins, and glycopeptides at some level. 
• Penalties: Denmark, California, and Maryland issue penalties to producers 
for failing to abide by the regulations set forth to slow antibiotic 
resistance. 
• Veterinary oversight: The European and California laws require a 
veterinarian to visit the form to prescribe antibiotics to food animals.  
o Denmark is the only country studied that does not require the 
establishment of a veterinarian-client-relationship. 
o The Netherlands is the only country that requires continuing education 
related to antibiotic use for veterinarians.  
• Monitoring and surveillance: Antibiotic resistance monitoring exists, 
though differs, for all of the countries.  
o The European countries monitor antibiotic use and California will 
begin monitoring this for producers who wish to volunteer. The United 
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States does not monitor use but it does monitor antibiotic sales 
information.  
o The European countries monitor resistance levels in food and resistant 
infections in animals and humans. At the national level in the United 
States, surveillance is limited for resistance levels in food and sporadic 
studies are conducted for resistant infections in animals; the country 
does monitor resistant infections in people both in the health-care 
setting and for certain enteric diseases.  
o Unlike the European countries, the United States does not require 
anyone to submit data on antibiotic use.  
• Required data submitters: Denmark and the Netherlands require 
veterinarians to report the antibiotics they administer. Producers in the 
Netherlands, but not in Denmark, are required to submit data.  
o Denmark also requires feed mills and pharmacies to report what 
antibiotics are sold to compare with the data for what vets administer.  
• Outcomes: The European policies have had success in reducing antibiotic 
use and resistance in animals. Results vary when it comes to overall 
reduction in resistant infections in people; Denmark reported no 
reductions while the Netherlands has some indications that its polices are 
reducing infections acquired within the country. 
Taken together, the studied European countries’ policies appear to be slowing the 
threat of antibiotic use. These countries also have robust surveillance systems which 
allow for continued trend monitoring. California appears to be aligning many of its 
policies with these European countries and expanding surveillance to include more 
monitoring. California’s policy may serve as a model that could be implemented at a 
national level.  
The next chapter explores policy options aimed at enhancing current strategies the 
United States has already employed to slow the threat of antibiotic resistance.  
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VII. CONCLUSIONS AND RECOMMENDATION 
The nation’s ability to respond to a bioterror or widespread disease event depends 
heavily on its medical countermeasures. The non-judicious use of antibiotics inhibits our 
ability to respond. Antibiotic resistance poses a massive threat to the health security of 
the homeland and warrants attention from the homeland security enterprise.  
The CDC lists several pathogens as “Category B” bioterrorism agents or 
diseases—“those that are moderately easy to disseminate; result in moderate morbidity 
rates and low mortality rates; and require specific enhancements of CDC’s diagnostic 
capacity and enhanced disease surveillance.”330 Included in the Category B list are 
Salmonella and Shigella—organisms also named by the CDC as serious drug-resistant 
threats to the United States.331 These organisms are present on farms, but there is little 
information about their prevalence and resistance. Because the United States has an 
uncoordinated approach to slowing the threat of antibiotic resistance, we are not well 
positioned to prevent outbreaks of resistant organisms or to preserve the medically 
necessary antibiotics currently available. We must look to interventions that will help 
mitigate the threat—and to do so, we must have better data that monitors use of 
antibiotics and tracks levels of resistance of drug-resistant organisms present on farms. 
In the United States, no single entity is responsible for collecting antibiotic 
surveillance information. Several disparate sources publish separate reports on different 
aspects of the threat, such as resistance among foodborne pathogens, sales data, and 
special studies on use and resistance in animals. As mentioned previously, NARMS has 
the qualities of an integrated system in that it includes both human and animal resistance 
information; however, it monitors foodborne organisms only. No U.S. system reports on 
all antibiotic use to identify whether reduction targets are necessary.  
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Veterinarians and producers also have a role to play in how antibiotics are used 
and administered to food animals. They should be actively involved in antibiotic 
administration, especially to ensure that antibiotics are not being used for non-therapeutic 
reasons or being overused for disease prevention.  
A. PROPOSED POLICY PACKAGE 
The previous chapter compared policy aspects of the case studies and the current 
U.S. strategies. Based on that review, this chapter discusses proposed policies that could 
enhance existing U.S. strategies. The policy package includes four potential strategies: 
1) creating an enhanced, more integrated surveillance system, 2) enacting antibiotic-use 
reduction targets, 3) prohibiting the use of antibiotics in healthy animals, and 4) requiring 
veterinarians to examine animals before they prescribe antibiotics for disease prevention.  
Each strategy has been assessed with the CDC’s policy analytical framework (see 
Table 1 and the Appendix) and is discussed in greater detail in the sections that follow. 
The Appendix assesses each policy option using framing questions to outline the scope 
and context of each policy; assesses the potential for the policy to impact risk factors, 
quality of life, disparities, morbidity, and mortality; examines the likelihood that the 
policy can be successfully adopted and implemented; and answers questions about the 
comparison of the costs to enact, implement, and enforce the policy with the value of 
benefits to the public. 
Table 8 summarizes and grades each strategy according to its potential impact and 
feasibility, and gives ratings for economic and budgetary impact. It should be noted that 
this thesis does not include robust cost-benefit analyses for each policy option—
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1. Creating an Integrated Surveillance System  
The first strategy proposed in this thesis is to create an integrated surveillance 
system to build upon the existing U.S. disease surveillance and antibiotic resistance data 
currently being collected. The integrated system would include information about 
resistant infections in people and animals and should be modeled after the Danish 
program, DANMAP, which was discussed in Chapter II. At a minimum, the system 
should monitor the consumption of antimicrobials in humans and animals and track 
antimicrobial-resistant bacteria found in animals, food, and people. Ideally, the system 
would allow analysts to identify the routes of transmission, whether from the farm, the 
environment, a health-care setting, or other means. In addition, the system should be 
robust enough to allow for the study of antimicrobial use and any links to emerging 
resistant organisms; additional research is needed in this area to plan for appropriate 
interventions to slow the threat of antimicrobial resistance. Given the small, sporadic 
studies about U.S. antimicrobial use as a contributor to antibiotic resistance, it is critical 
to put a national system in place that allows study on a larger scale.  
Industry has not interpreted these small studies to indicate potential risks to public 
health. The Animal Health Institute, an association whose members are all 
pharmaceutical companies, continues to claim that “current science can’t really prove 
what causes all of the different types of antimicrobial resistance that create public health 
risks.”333 The institute also opines, “The assumption that simply giving antimicrobials to 
a larger number of animals creates a public health hazard due to resistance isn’t accurate, 
because it doesn’t account for the benefits of preventing disease and the need for higher 
doses and potentially stronger types of antimicrobials if an animal is sick.”334 Given the 
vocal and disparate opinions, the most important first step is to be able to factually 
resolve the issue. This requires data. Therefore, a national surveillance system that would 
contribute to the science of monitoring antibiotic resistance is essential to examine how 
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detrimental antibiotic use in agriculture is, and where to prioritize interventions to slow 
the threat if necessary. Although this thesis does not discuss human contributions to 
antibiotic resistance, an integrated system like Denmark’s would create a holistic view of 
where to focus efforts and would allow us to better evaluate policy needs or 
effectiveness—whether in a farm or health-care setting.  
Building the proposed surveillance system infrastructure would require 
collaboration between the FDA, USDA, and CDC, with support from the Department of 
Homeland Security. Legal policies would need to be enacted to compel veterinarians, 
producers, and health-care providers to submit information on antimicrobials prescribed 
and used, as well as information they obtain on antimicrobial resistance through testing of 
isolates from illness in animals and humans. The illness information could be facilitated 
through electronic laboratory reporting. The data collected in the system could then be 
linked with the FDA’s antibiotic sales data to examine the full antibiotic supply chain, 
from manufacturer to user, and provide critical data for decision-making and trend 
monitoring. The information submitted on resistant pathogens in health-care through the 
National Healthcare Safety Network could be combined with the information already 
collected in NARMS to create a holistic picture of resistant organisms in the United 
States. To ensure compliance, penalties would likely need to be enacted for 
noncompliance. 
As shown in the policy analysis table presented previously (Table 8), this policy 
would have a large reach but may face some opposition given the reporting burden 
required of veterinarians, human health-care providers, and farmers. Human health-care 
providers have been required to report resistant infections as part of national and local 
notifiable disease reporting requirements; however, antimicrobial use reporting has never 
been required. This could be challenging to implement, but the infrastructure could be 
based largely on what is required currently for opioid prescriptions to combat the opioid 
overdose epidemic. For example, states have enacted prescription drug monitoring 
programs (PDMPs), which create a “database that tracks controlled substance 
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prescriptions in a state.”335 Each time a pharmacist fills a prescription for a controlled 
substance, he or she must record it into a state’s PDMP.336 PDMPs provide surveillance 
on who may be heavy prescribers, as well as who may be heavy users.337 They give 
health officials the ability to apply targeted interventions to address the problem. 
Veterinarians and farmers, however, could see a PDMP-like surveillance system for 
antibiotic use in agriculture as overly burdensome; in the past, the Animal Health 
Institute has lobbied against more transparency regarding the use of antibiotics in 
animals.338  
The potential costs for enacting this policy are unknown, and a robust cost-benefit 
analysis should be performed. It is also difficult to estimate the benefits of this system 
given that it is not an intervention, per se. This system would help create an accurate 
picture of agriculture’s contribution to the accelerating rate of antibiotic resistance. The 
desire to conduct robust cost-benefit analyses of the policy interventions recommended in 
this thesis depends on the scope of the problem, which cannot truly be defined until a 
more integrated surveillance system is implemented. That said, this thesis considers this 
policy option to have moderate costs based on implementation of the necessary 
technology. Costs are low, however, relative to the benefits to health security: the benefit 
of this particular system is that the United States would finally have proof of the problem 
and policymakers could implement interventions (those outlined in the subsequent 
sections) based on accurate information.  
2. Enacting Antibiotic-Use Reduction Targets 
The next strategy, enacting antibiotic-use reduction targets, is dependent on the 
implementation of the surveillance system discussed in the previous section. There is no 
feasible way to institute antibiotic use targets unless there is a more robust data system to 
determine if targets are being met. If an integrated surveillance system were in place, the 
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USDA and FDA could collaborate to set antibiotic use targets for the farming industry. 
Legislation or administrative rule would need to be established to allow the USDA to set 
mandatory targets, and an administrative structure would need to be created. Penalties 
could be imposed for entities that do not meet established benchmarks.  
This strategy could be adapted from the Dutch benchmarking model, the SDa. 
The Netherlands Veterinary Medicines Institute created what it calls an expertpanel, 
which includes scientists with expertise in epidemiology, veterinary medicine, and human 
health. The panel examines antibiotic use information and establishes benchmarks for the 
types of drugs that should be used as well as the amount for each food-animal sector, and 
has the ability to consult with another group of scientists for technical feedback. The SDa 
has a board that works with a supervisory commission and an advisory council of 
stakeholders. The expertpanel reports to this board. A similar structure could be created 
in the United States that works with the USDA and FDA.  
It does not appear that a strategy like this one has been discussed previously in the 
United States, so there is no historical perspective of potential opposition. However, it is 
likely that the farming industry and pharmaceutical companies would oppose reduction 
targets due to their past objections to regulation in this context.  
As shown in the policy analysis table (Table 8), this proposal would have a high 
impact; it would have a large reach in reducing the use of antibiotics. However, due to the 
likelihood of strong opposition, this policy option has a low feasibility score and has little 
to no likelihood of being enacted. In terms of the governmental impact, the costs may be 
relatively low to implement but there could be significant financial effects for the 
agriculture industry and pharmaceutical companies. Initially there may be animal losses 
as farmers find different methods that do not rely on antibiotics, and the pharmaceutical 
companies could face financial losses with fewer antibiotics being sold. That said, this 
thesis proposes that the costs to implement reduction targets would be relatively low 
compared with the overall benefit to humanity.  
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3. Prohibiting the Use of Medically Important Antibiotics in Healthy 
Animals 
The third strategy would prohibit the use of antibiotics in healthy animals unless 
disease has been diagnosed in other animals in the same flock or herd. The policy would 
ensure that antibiotics are not provided to animals for non-therapeutic purposes, including 
routine disease prevention. This means that farmers would not be able to administer 
antibiotics to prevent disease solely because their animals are kept in close quarters or to 
use antibiotics in animals during transport—a practice that is allowed under the current 
FDA judicious use guidance.  
This policy would require legislation or FDA guidance/rules and would likely 
require a phased implementation period to ascertain which drugs cannot be used for non-
therapeutic purposes. As shown in Table 8 earlier in this chapter, this policy could have a 
high impact on antibiotic overuse in agriculture based on the European case study 
findings discussed in previous chapters. It also would have relatively low costs to 
implement in terms of the governmental role but could sustain significant costs in the 
agriculture industry, as producers would need to change their farming practices to 
achieve a highly bio-secure environment. The costs to implement are low relative to the 
overall benefits to human medicine.  
This policy has low feasibility, with little to no likelihood of being enacted. The 
concept been introduced in legislation over the past two decades through the Preservation 
of Antibiotics for Medical Treatment Act, which would make it illegal to give medically 
important antimicrobials to food animals for non-routine disease control.339 The act has 
been introduced, in some form, since 1999 and has not passed. It is therefore unlikely that 
a policy measure like this one would pass. Such proposed legislation would meet 
resistance from the agriculture industry due to the necessary changes in farming 
practices.  
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4. Requiring Annual Veterinary Examinations for Disease Prevention 
and Control  
The final policy as part of this proposed package would require veterinarians, on 
an annual basis, to physically examine animals before they can prescribe antibiotics for 
prophylaxis. The veterinarian would, using professional judgment, decide if preventive 
treatment is needed to protect a herd against illness. This strategy is based on current 
policies in the Netherlands and California. The policy in the Netherlands requires 
veterinarians to administer all antimicrobials, and the country requires a veterinarian-
client relationship that includes periodic inspections of the farm. However, farmers may 
be provided antibiotics without a vet visit if they have established their relationship with 
the veterinarian and inspections have been performed.340  
It does not appear that this type of policy has been debated at the national level; 
however, similar requirements have been debated at the state level in California. The 
California laws do not require a visit or a physical examination for each potential disease 
incident before antibiotics can be prescribed, but they do require the establishment of a 
veterinarian-client relationship for animal patients (with the exception of wild animals). 
This relationship requires the veterinarian to be “personally acquainted with the animal(s) 
by virtue of an examination of the animal or by medically appropriate and timely visits to 
the premises where the animals are kept.”341  
The USDA has recorded at least one veterinarian shortage situation in most states 
in the United States, which means that there are not enough veterinarians to provide basic 
animal health services and/or services related to the food supply or public health.342 
Therefore, a visit for each instance of potential disease risk may not be practical. This 
thesis proposes an annual veterinary examination under a veterinary-client relationship. 
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This policy would require legislation and would likely need to be implemented at the 
state level, given that veterinarians are licensed to practice by individual states. To track 
veterinary-client relationships, data would need to be collected at the state level. These 
data would then need to be aggregated at the national level to develop an overview of 
how well the system is functioning.  
As shown previously in Table 8, this policy option has the potential to create a 
high impact given that drugs cannot be administered without the intervention of a 
veterinarian. This could be palatable to the industry since veterinary oversight is already 
required by the FDA in order to have a veterinary feed directive.343 In terms of the 
budgetary impact, this policy would have moderate costs to implement in government. 
This thesis proposes penalties for entities who violate the policy, which would require 
some level of enforcement from the USDA or state departments of agriculture. Many 
producers have already established relationships with veterinarians, who may already be 
visiting the farms annually; therefore, the costs to implement may not be significant to 
industry. 
B. RECOMMENDATION 
This thesis recommends that all four policies are implemented as a package; the 
policies on their own do not stand to make a large impact to slowing the threat of 
antibiotic resistance. However, given the history of policymaking related to antibiotic 
resistance and agriculture in the United States, it is unlikely that the full policy package 
would be adopted together.   
Therefore, this thesis proposes that the U.S. government implement these policies 
in a phased approach beginning with the first policy—enhancing data collection and 
building an integrated surveillance system. This strategy should be prioritized over the 
other three simply because it is foundational and serves as necessary infrastructure to 
promote informed decision-making about antibiotic resistance. Even though there are 
numerous scientific studies about the link between antibiotic use and antibiotic resistance, 
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the evidence leaves industry and policymakers unconvinced that more interventions are 
needed in the United States. An integrated system would be a first step to make the link 
between antibiotic use and resistant organisms among food animals more visible. Perhaps 
then, the general public, policymakers, and the agriculture and pharmaceutical industries 
would collectively engage to address this threat in the United States.  
Once an integrated surveillance system is implemented, antibiotic-use reduction 
targets can be set. If the targets are not being met, more interventions could be deployed, 
such as prohibiting the use of antibiotics in healthy animals or requiring an annual 
veterinary exam, or perhaps requiring an exam before administering antibiotics for every 
instance of disease risk. Iterative steps can be taken to achieve a reduction in the use of 
antibiotics in food animals. While this approach would likely not see quick results, 
implementation would be easier and would likely allow industry to shape how the 
policies are enacted to ensure the least amount of disruption to businesses.  
For any of these policies to be enacted, all stakeholders must be present and 
actively engaged; outreach should begin at the individual farm level. It is important to 
ensure that there are educational campaigns that reach farmers—not just industry 
associations. Individual producers must be informed about the threat of antibiotic 
resistance and be encouraged to be active participants in finding solutions.  
There is limited information in the literature about the perceptions and attitudes 
regarding antibiotic resistance among U.S. livestock producers (as opposed to the 
industry associations). One study, conducted among rural South Carolina dairy farmers, 
indicated that while all farmers were utilizing some procedures to assess whether or not 
antibiotics were needed, only 32 percent of them had documented systematic 
procedures.344 In addition, 86 percent of those surveyed “were not concerned that 
overuse of antibiotics in animals could result in antibiotic resistance among farm 
workers.”345 The study also described perceived barriers to following proper antibiotic 
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administration procedures—namely, limited financial resources and time. The 
participants also discussed a need to have bilingual educational materials for farm 
workers to ensure all are educated on proper antibiotic administration. It should be noted, 
however, that the study was published in 2007, which means the knowledge base on risks 
of antibiotic resistance and proper administration of antibiotics may have since improved, 
as interventions have been implemented by the FDA and USDA. However, the key 
findings indicate that more education is needed on risks and judicious use of antibiotics, 
which is presumably still a need.  
One way to reach farmers is through veterinarians. In the aforementioned study of 
South Carolina farmers, 100 percent of participants indicated that their preferred 
information sources about antibiotics were veterinarians.346 Veterinarians have an 
integral role in antibiotic stewardship practices in agriculture, as has been discussed in the 
policy recommendations in this thesis; however, they are also key to educating producers 
about the risks of overuse of antibiotics and judicious use. It is essential to hear first-hand 
input from livestock producers about how to implement policies in a way that is 
minimally intrusive and burdensome—and this can be done in collaboration with 
veterinarians. When governments make decisions for their people without the peoples’ 
feedback, the outcome is usually not positive: people resist and goals are not achieved. 
However, by working together on action steps and implementation plans, it is possible to 
achieve lofty goals. This type of approach was successful in Europe; in Denmark and the 
Netherlands, the producers were included in the discussions and most believed they were 
part of the solution.  
C. FUTURE RESEARCH OPPORTUNITIES 
This thesis described several case studies that focused on antibiotic use in 
agriculture, but many aspects of this issue were out of scope of this thesis. It is important 
that work continues to better understand this complex problem and examine emerging 
solutions that show promise in slowing the threat of antibiotic resistance.  
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First, policies that have been implemented should be evaluated. Much of the 
research published on the case studies does not evaluate the policies themselves, but is 
more statistical and epidemiological in nature. Better policy evaluation and assessment is 
needed to ensure that the policies are effective—Do they achieve what they intended to 
achieve and, if not, why?  
In addition, several interventions other than legislative bans could be evaluated 
for their potential to curb the threat. This thesis touched briefly on production practices 
implemented in the European case study countries after their legislative bans, but more 
research should be conducted to determine if U.S. industrial operations could adopt some 
of the production practices in Denmark and the Netherlands to ensure that routine 
prophylaxis is not necessary. Some public health officials argue that the conditions in 
which food animals are raised in industrial operations in the United States may be partly 
to blame for the rise in the use of antibiotics and the acceleration of antibiotic 
resistance.347 Animals kept in close quarters in unsanitary conditions with weakened 
immune systems are more susceptible to infections, thus small doses of antibiotics are 
used as prophylaxis to ensure the animals do not become ill. Antibiotic use in this manner 
is likely to continue without regulation or widespread change to farming practices.  
There are also other interventions that have not been explored in this thesis, such 
as evaluating the effectiveness of organizations in the United States that aim to educate 
interested veterinarians and farmers on antimicrobial stewardship and that work together 
to create plans that ensure proper drug use. In addition, this thesis did not investigate 
what role, if any, organic farming might play in addressing the threat of antibiotic 
resistance. These avenues could provide insights into other voluntary methods that 
individual producers could take if regulatory options are not sought.  
This thesis focused solely on the administration of antibiotics to food animals; it 
did not discuss another important byproduct of farms and a source of antibiotic-resistant 
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organisms: manure. There must be more research done on effective waste-management 
strategies on farms to eliminate modes of transmission between animals and people.  
Furthermore, additional research should examine antibiotic resistance and pets. 
People live in close quarters with their animals, which increases the risk for sharing 
resistant organisms. There is limited information available regarding antibiotic use in pets 
and it is important to include this aspect of antibiotic administration as well as potential 
transmission modes in a surveillance system—especially considering the rising number 
of people who own backyard poultry that should be monitored.  
Finally, this thesis did not explore farmer and veterinarian knowledge and 
attitudes about antibiotic resistance in great depth. It is possible that interventions not 
considered here would have a limited impact on the industries.  
D. CONCLUSION 
While the World Health Organization’s study concluded that the Danish 
experience could be replicated in countries where the industry model operates similarly, 
the FDA and USDA have operated under the assumption that a ban on the use of 
antibiotics for growth promotion in livestock would not be adopted in the United States. 
This is unsurprising given that many industry groups do not widely accept that overuse of 
antibiotics in food animals contributes to antibiotic resistance. With the USDA’s 
commitment to more surveillance, the FDA’s guidance to industry on the judicious use of 
antimicrobials, and the voluntary changes that are being made by industry, the United 
States is at least acknowledging that it must engage in the conversation and pursue some 
solutions to this emerging threat. However, the current strategies are likely not enough to 
mitigate our country’s contribution to this problem.  
This thesis analyzed efforts in Europe and two U.S. states, and provided several 
strategies that could be employed at the national level that would bring the United States 
in line with other large agricultural industries in terms of its commitment to global health 
security. Antibiotic resistance will continue to be a global public health and homeland 
security threat if efforts to reduce reliance on antibiotics in animal husbandry are not 
strengthened. It is important to engage farmers and veterinarians and ensure they are 
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committed to finding solutions to this issue. Congress, the FDA, and the USDA should 
look to the successes of other nations that have actively responded to this global threat. 
The agencies should continue to work with industry partners to gain buy-in and 
acceptance of responsibility and duty to preserve medically important antibiotics to 
protect the health and safety of people and animals.  
The research in this thesis has outlined several reasons why the United States has 
taken limited steps to implement strategies to curb the threat of antimicrobial resistance 
in the agriculture sector. This threat cannot continue to be ignored in the name of 
immediate expense or burdens to a sector—the costs to humanity are too great. Studying 
the response to this problem through a homeland security lens has illuminated a risk 
assessment issue for those who oppose restrictions on the use of antibiotics in an 
agricultural setting and science. This is a grave risk, regardless of the lack of evidence 
that every resistant organism can be traced to antibiotic use in livestock.  
Science shows that people are being infected with multidrug resistant organisms 
through exposure to livestock that have developed drug-resistant bacteria because of the 
use of antibiotics. If the use is reduced, so is the resistance. This has been studied and 
proven yet, as a nation, this problem has been largely ignored. The homeland security 
enterprise should prioritize antibiotic resistance as a threat and work collaboratively to 
implement the strategies outlined in this thesis to mitigate it.  
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APPENDIX.  PROPOSED POLICY ANALYSIS 
This appendix analyzes the four potential strategies that could enhance current 
approaches the United States has already employed to slow the threat of antibiotic 
resistance. The policies are: 
• Creating an enhanced, more integrated surveillance system 
• Enacting antibiotic-use reduction targets 
• Prohibiting the use of antibiotics in healthy animals 
• Requiring veterinarians to examine animals before they prescribe 
antibiotics for disease prevention 
Using the CDC’s policy analytical framework, each of these strategies is analyzed in the 
following tables. 
Table 9. Policy Package—Integrated Surveillance System 
Framing questions  
What is the policy lever—is it legislative, 
administrative, regulatory, other? 
Legislation. 
What level of government or institution will 
implement? 
Federal government. 
How does the policy work/operate? (e.g., Is it 
mandatory? Will enforcement be necessary? 
How is it funded? Who is responsible for 
administering the policy?) 
This would need to be a partnership 
between the FDA, USDA, and CDC with 
assistance from DHS. The policy would 
require veterinarians, producers, and health- 
care providers to report antimicrobial 
prescribing and use data. There may need to 
be consequences for entities who do not 
report.  
What are the objectives of the policy? This policy allows for a holistic view of where 
to focus efforts to slow the threat of 
antibiotic resistance and would assist in the 
evaluation of existing policy or demonstrate 
a need for new policy.  
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Framing questions  
What is the legal landscape surrounding the 
policy (e.g., court rulings, constitutionality)? 
There would be concerns about 
confidentiality on the part of the data 
reporters, along with how the data would be 
used and disseminated. 
What is the historical context (e.g., Has the 
policy been debated previously)? 
Yes. Legislation has been introduced in the 
past for mandatory reporting of 
antimicrobial use in agriculture; however, 
larger integrated system has not been 
proposed. There has been limited discussion 
of implementing a system that integrates 
human antimicrobial use and animal use. 
What are the expected short-, intermediate-, 
and long-term outcomes? 
Short term, this policy would create baseline 
data. Intermediate would be to use the data 
to view trends. Long term it could be used 
for evaluating the effectiveness of various 
interventions. 
What might be the unintended positive and 
negative consequences of the policy? 
Unintended negative consequences would 
be a large reporting burden on farmers, 
human health-care providers, and 
veterinarians. Positive consequences include 
this system being leveraged for global use.  
 
Potential for the policy to impact risk factors, quality of life, disparities, morbidity, and 
mortality 
How does the policy address the problem or 
issue (e.g., increase access, protect from 
exposure)? 
This policy allows government to make 
informed decisions about interventions to 
slow antibiotic resistance. 
What are the magnitude, reach, and 
distribution of benefit and burden (including 
impact on risk factor, quality of life, morbidity, 
and mortality)? 
• What population(s) will benefit? How 
much? When? 
• What population(s) will be negatively 
impacted? How much? When? 
This is a global problem. The United States 
would only be able to monitor the trends in 
the country. The surveillance system itself 
would benefit government agencies, 
scientists, researchers, farmers, 
veterinarians, health-care providers, 
animals, and people. 
Will the policy impact health disparities/
health equity? How? 
This policy strategy does not impact health 
disparities.  
Are there gaps in the data/evidence base? It is not known what the impact of this 
particular strategy would be. However, the 





Likelihood that the policy can be successfully adopted and implemented 
What are the current political forces, including 
political history, environment, and policy 
debate? 
Reporting requirements have not been 
welcomed by the farming industry. 
Veterinarians may be more accepting. 
Health-care providers typically do report 
resistant infections as part of nationally 
requirements, but none have been required 
to report antimicrobial use.  
Who are the stakeholders, including 
supporters and opponents? What are their 
interests and values? 
Veterinarians, human health-care providers, 
and farmers. This would be viewed as overly 
burdensome to report. 
What are the potential social, educational, 
and cultural perspectives associated with the 
policy option (e.g., lack of knowledge, fear of 
change, force of habit)? 
This would be viewed as additional 
regulation and a burden upon farmers.  
What are the potential impacts of the policy 
on other sectors and high-priority issues (e.g., 
sustainability, economic impact)? 
This would require a commitment from 
Congress to fund the data collection system 
at the federal level.  
What are the resource, capacity, and technical 
needs for developing, enacting, and 
implementing the policy? 
Unknown. 
How much time is needed for the policy to be 
enacted, implemented, and enforced? 
Unknown. 
How scalable, flexible, and transferable is the 
policy? 
This would be nationwide, so it is possible it 
could be leveraged to be used globally. 
 
Comparison of the costs to enact, implement, and enforce the policy with the value of the 
benefits 
What are the costs and benefits associated 
with the policy from a budgetary perspective? 
(e.g., for public—federal, state, local—and 
private entities to enact, implement, and 
enforce the policy?) 
Unknown. There would be some costs for 
the producers and veterinarians to report 
information, and there would be costs to the 
government to set up the system.  
How do costs compare to benefits (e.g., cost 
savings, costs averted, ROI, cost-effectiveness, 
cost-benefit analysis, etc.)? 
• How are costs and benefits distributed 
(e.g., for individuals, businesses, 
government)? 
• What is the timeline for costs and 
benefits? 
Unknown. 
Where are there gaps in the data/evidence 
base? 
Further research is needed to determine 
what it would cost to implement an 
integrated surveillance system in the United 
States.  
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Table 10. Policy Package—Antibiotic-Use Reduction Targets 
Framing questions  
What is the policy lever—is it legislative, 
administrative, regulatory, other? 
Administrative. 
What level of government or institution will 
implement? 
Federal government. 
How does the policy work/operate? (e.g., Is it 
mandatory? Will enforcement be necessary? 
How is it funded? Who is responsible for 
administering it?) 
The USDA will set mandatory antibiotic use 
targets for agriculture but can only do so if 
the previous policy strategy is implemented. 
There will be no way to know where to set 
targets unless a baseline is established 
through data collection.  
What are the objectives of the policy? The objective is to see a reduction in the use 
of antibiotics in general.  
What is the legal landscape surrounding the 
policy (e.g., court rulings, constitutionality)? 
None. 
What is the historical context (e.g., Has the 
policy been debated previously)? 
This does not appear to have been debated 
in the United States. However, the 
Netherlands and Denmark have both had 
targets implemented. 
What are the expected short-, intermediate-, 
and long-term outcomes? 
A long-term overall reduction in the use of 
antibiotics in livestock, thus reducing the 
prevalence of antibiotic resistance.  
What might be the unintended positive and 
negative consequences of the policy? 
There could be more sick animals if farmers 
are not relying on vets to help them meet 
antibiotic use targets, or if they are not 
employing different farming practices to 
promote better infection control/prevention. 
 
Potential for the policy to impact risk factors, quality of life, disparities, morbidity and 
mortality 
How does the policy address the (e.g., 
increase access, protect from exposure)? 
Setting mandatory goals will reduce 
antibiotic use and resistance on farms.  
What are the magnitude, reach, and 
distribution of benefit and burden (impact on 
risk, quality of life, morbidity, and mortality)? 
• What population(s) will benefit? How 
much? When? 
• What population(s) will be negatively 
impacted? How much? When? 
Animals could potentially be negatively 
impacted. Farmers could be negatively 
impacted by financial losses. Farmers will be 
less likely to contract a drug-resistant 
infection if there are fewer resistant 
organisms on their farms due to reduced 
antibiotic use.  
Will the policy impact health disparities/
health equity? How? 
No.  
Are there gaps in the data/evidence base? It is difficult to assess the impact in the 
United States, but European experiences 
could be examined.  
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Likelihood that the policy can be successfully adopted and implemented 
What are the current political forces, including 
political history, environment, and policy 
debate? 
The farming industry would likely oppose 
this policy. It will be perceived as an 
overreach in regulation. 
Who are the stakeholders, including 
supporters and opponents? What are their 
interests and values? 
The farming industry and associations will be 
against this, as will pharmaceutical 
companies. Public health organizations and 
the medical and scientific community would 
be in favor.  
What are the potential social, educational, 
and cultural perspectives associated with the 
policy option (e.g., lack of knowledge, fear of 
change, force of habit)? 
Lack of knowledge about the issue of 
antibiotic resistance among farmers could 
contribute to a perception of overregulation.  
What are the potential impacts of the policy 
on other sectors and high-priority issues (e.g., 
sustainability, economic impact)? 
The pharmaceutical industry has argued 
market restrictions in antibiotic use may 
accelerate resistance. Introducing new drugs 
is key to addressing resistance; there are 
limited incentives for drug companies to 
develop new agents. The industry asserts 
that restrictions on antibiotics would result 
in lost earning potential. In addition, strict 
regulations increase development costs. 
Because of these factors, antibiotics are not 
an attractive economic choice for new drug 
development.348 The world will continue to 
rely on existing antibiotics, resulting in 
accelerating resistance because of limited 
options. However, many of the antibiotics 
used in the animal industry are also off 
patent and companies that are selling these 
products may not be the same as those 
developing new products. The loss of sales in 
the animal sector may have no impact on the 
development of new antibiotics. 
What are the resource, capacity, and technical 
needs developing, enacting, and 
implementing the policy? 
This policy would require limited resources; 
however, an enforcement component would 
increase this substantially. 
How much time is needed for the policy to be 
enacted, implemented, and enforced? 
Likely two years. 
How scalable, flexible, and transferable is the 
policy? 
This would probably be very specific to the 
United States. Transferability would be 
limited.  
                                                 
348 E. Power, “Impact of Antibiotic Restrictions: The Pharmaceutical Perspective,” Clinical 
Microbiology and Infection 12 (August 1, 2006): 25–34, https://doi.org/10.1111/j.1469-0691.2006.01528.x. 
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Comparison of the costs to enact, implement, and enforce the policy with the value of the 
benefits 
What are the costs and benefits associated 
with the policy, from a budgetary perspective? 
(e.g., for public—federal, state, local—and 
private entities to enact, implement, and 
enforce the policy?) 
The costs would be limited and the benefits 
to society as a whole would be large.  
How do costs compare to benefits (e.g., cost 
savings, costs averted, ROI, cost effectiveness, 
cost-benefit analysis, etc.)? 
• How are costs and benefits distributed 
(e.g., for individuals, businesses, 
government)? 
• What is the timeline for costs and 
benefits? 
The costs would be limited and the benefits 
to society as a whole would be large. 
Where are there gaps in the data/evidence 
base? 
More research is needed to develop a fiscal 
analysis on what this would cost.  
 
Table 11. Policy Package—Prohibit the Use of Antibiotics in Healthy Animals 
Framing questions  
What is the policy lever—is it legislative, 
administrative, regulatory, other? 
Legislative or administrative guidance issued 
to veterinarians. 
What level of government or institution will 
implement? 
Federal government. 
How does the policy work/operate? (e.g., Is it 
mandatory? Will enforcement be necessary? 
How is it funded? Who is responsible for 
administering the policy? 
This policy would prohibit the use of 
antibiotics in healthy animals UNLESS disease 
has been diagnosed in other animals in the 
same flock or herd. This policy does not 
consider environmental factors or transport 
to be evidence of elevated bacterial disease 
risk. 
What are the objectives of the policy? This policy ensures that antibiotics are not 
provided to animals for non-therapeutic 
purposes, including routine disease 
prevention.  
What is the legal landscape surrounding the 
policy (e.g., court rulings, constitutionality)? 
None. 
What is the historical context (e.g., Has the 
policy been debated previously)? 
This policy has been introduced as part of 
the Preservation of Antibiotics for Medical 
Treatment Act, introduced by the late Louise 
Slaughter of New York. 
Framing questions  
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What are the expected short-, intermediate-, 
and long-term outcomes? 
In the short term, it is possible that more 
animals would become ill because of 
production practices. Intermediate outcomes 
could include changes in farming practices 
and increased production, as seen in 
Denmark. Long term, the country should see 
less antibiotic-resistant organisms in meat 
and less resistant infections in animals and 
people. 
What might be the unintended positive and 
negative consequences of the policy? 
Unintended negative consequences include 
significant financial losses for farmers due to 
illness in animals. 
 
Potential for the policy to impact risk factors, quality of life, disparities, morbidity, and 
mortality 
How does the policy address the problem or 
issue (e.g., increase access, protect from 
exposure)? 
This policy ensures the judicious use of 
antibiotics to assist with reducing antibiotic 
resistance. 
What are the magnitude, reach, and 
distribution of benefit and burden (including 
impact on risk factor, quality of life, morbidity, 
and mortality)? 
• What population(s) will benefit? How 
much? When? 
• What population(s) will be negatively 
impacted? How much? When? 
There will be less antibiotic-resistant 
infections in animals and people. 
If producers do not work to change 
production practices, there may be more 
infections and morbidity among animals in 
the short term, which will increase costs to 
the producers.  
Will the policy impact health disparities/
health equity? How? 
No. 
Are there gaps in the data/evidence base? Yes. It is unclear how much impact this policy 
would have in the United States without 
additional changes to farming operations.  
 
Likelihood that the policy can be successfully adopted and implemented 
What are the current political forces, including 
political history, environment, and policy 
debate? 
The agriculture industry would likely be 
opposed to this type of prohibition given 
historical opposition to similar bills.  
Pharmaceutical companies would also likely 
be opposed.  
Previous bills have never made it out of 
legislative committee.  
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Likelihood that the policy can be successfully adopted and implemented 
Who are the stakeholders, including 
supporters and opponents? What are their 
interests and values? 
Agriculture industry, pharmaceutical 
companies, veterinarians, the general public. 
The agriculture industry would want to 
ensure animal health and a profitable 
industry. Pharmaceutical companies would 
want to ensure they do not lose money and 
veterinarians to ensure animal health. The 
general public wants to slow antibiotic 
resistance; however, they want to ensure 
that the food supply is not harmed and that 
prices do not go up due to the policy change.  
What are the potential social, educational, 
and cultural perspectives associated with the 
policy option (e.g., lack of knowledge, fear of 
change, force of habit)? 
This would likely require a phase-in approach 
to allow the industry the opportunity to 
adapt its practices (e.g., improve biosecurity 
to reduce risk of disease transmission).  
What are the potential impacts of the policy 
on other sectors and high-priority issues (e.g., 
sustainability, economic impact)? 
Unknown. 
What are the resource, capacity, and 
technical needs developing, enacting, and 
implementing the policy? 
The policy would not require capacity to 
implement at a governmental level, but 
capacity to provide outreach and technical 
assistance would be needed to ensure that 
producers and veterinarians know what is 
expected of them. This could be extensive. If 
producers need to change their practices, 
this may require advisement from experts.  
How much time is needed for the policy to be 
enacted, implemented, and enforced? 
Unknown. This would be a phased-in policy 
likely over several years, possibly 5 years 
after enacted, to allow producers to comply. 
How scalable, flexible, and transferable is the 
policy? 
This policy could potentially be leveraged in 
other countries.  
 
Comparison of the costs to enact, implement, and enforce the policy with the value of the 
benefits 
What are the costs and benefits associated 
with the policy, from a budgetary perspective? 
(e.g., for public—federal, state, local—and 
private entities to enact, implement, and 
enforce the policy?) 
A fiscal note would be needed for 
government implementation. The possible 
costs to industry are unknown but likely 
sizeable given necessary changes to farming 
practices, the potential for illnesses in the 
short term, and potential animal loss.  
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Comparison of the costs to enact, implement, and enforce the policy with the value of the 
benefits 
How do costs compare to benefits (e.g., cost 
savings, costs averted, ROI, cost effectiveness, 
cost-benefit analysis, etc.)? 
• How are costs and benefits distributed 
(e.g., for individuals, businesses, 
government)? 
• What is the timeline for costs and 
benefits? 
Long-term benefits are immeasurable—the 
threat of antibiotic resistance will slow 
enough to allow pharmaceutical companies 
to research and develop new therapies. It 
could take decades to see the effects.  
Where are there gaps in the data/evidence-
base? 
The industries will likely argue that there is 
insufficient evidence that reducing antibiotic 
use in agriculture reduces resistant infections 
in people.  
Table 12. Policy Package—Annual Veterinary Examination for Prophylaxis 
Framing questions  
What is the policy lever—is it legislative, 
administrative, regulatory, other? 
Legislative. 
What level of government or institution will 
implement? 
Federal and state partnership. 
How does the policy work/operate? (e.g., Is it 
mandatory? Will enforcement be necessary? 
How is it funded? Who is responsible for 
administering the policy?) 
This policy would require the establishment 
of a veterinary-client relationship among 
producers and veterinarians and would 
require at least one physical examination of 
animals before they are prescribed 
antibiotics for prophylaxis. The veterinarian 
would, using professional judgment, decide 
if preventive treatment is needed to protect 
a herd when there is evidence of disease. 
What are the objectives of the policy? This policy aims to ensure judicious use of 
antibiotics in farm animals. 
What is the legal landscape surrounding the 
policy (e.g., court rulings, constitutionality)? 
None. 
What is the historical context (e.g., Has the 
policy been debated previously)? 
This does not appear to have been debated 
in the United States at a national level. It has 
been debated at the state level in California 
with the requirement of establishing 
veterinarian-client relationships.  
What are the expected short-, intermediate-, 
and long-term outcomes? 
Healthy animals with the lowest amount of 
antibiotics used.  
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Framing questions  
What might be the unintended positive and 
negative consequences of the policy? 
It may be difficult for herds to receive an 
annual visit/exam and would exacerbate an 
already taxed veterinary workforce.  
 
Potential for the policy to impact risk factors, quality of life, disparities, morbidity, and 
mortality 
How does the policy address the problem or 
issue (e.g., increase access, protect from 
exposure)? 
This policy ensures the judicious use of 
antibiotics to assist with reducing antibiotic 
resistance.  
What are the magnitude, reach, and 
distribution of benefit and burden (including 
impact on risk factor, quality of life, morbidity, 
and mortality)? 
• What population(s) will benefit? How 
much? When? 
• What population(s) will be negatively 
impacted? How much? When? 
The animals will benefit by ensuring that 
they have been examined and given 
appropriate treatment or prevention.  
Farmers will likely need to pay more for 
more visits.  
Fewer resistant infections for people and 
animals.  
Will the policy impact health disparities/
health equity? How? 
No. 
Are there gaps in the data/evidence base? The total impact on these populations is 
unknown. 
 
Likelihood that the policy can be successfully adopted and implemented 
What are the current political forces, including 
political history, environment, and policy 
debate? 
This may be palatable given that every farm 
now must have a veterinary oversight per 
the FDA in order to have a veterinary feed 
directive.349  
Who are the stakeholders, including 
supporters and opponents? What are their 
interests and values? 
Veterinarians could be for this, but they 
might be worried about having enough 
human capital in the field to keep up with 
the demand. 
 
What are the potential social, educational, 
and cultural perspectives associated with the 
policy option (e.g., lack of knowledge, fear of 
change, force of habit)? 
Unknown.  
What are the potential impacts of the policy 
on other sectors and high-priority issues (e.g., 
sustainability, economic impact)? 
If fewer antibiotics are being used, this will 
have an impact on the pharmaceutical 
companies.  
  
                                                 
349 FDA Center for Veterinary Medicine, “Guidance for Industry #213.” 
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Likelihood that the policy can be successfully adopted and implemented 
What are the resource, capacity, and technical 
needs developing, enacting, and 
implementing the policy? 
The policy would not require a lot of capacity 
to implement at a governmental level, but 
technical assistance would be needed to 
ensure that veterinarians and farmers knew 
what was expected of them to comply.  
How much time is needed for the policy to be 
enacted, implemented and enforced? 
Unknown. 
How scalable, flexible, and transferable is the 
policy? 
This could be leveraged in other countries.  
 
Comparison of the costs to enact, implement, and enforce the policy with the value of the 
benefits 
What are the costs and benefits associated 
with the policy, from a budgetary perspective? 
(e.g., for public—federal, state, local—and 
private entities to enact, implement, and 
enforce the policy?)  
It is unknown what this will cost farmers; 
government cost will be limited.  
How do costs compare to benefits (e.g., cost 
savings, costs averted, ROI, cost effectiveness, 
cost-benefit analysis, etc.)?  
• How are costs and benefits distributed 
(e.g., for individuals, businesses, 
government)? 
• What is the timeline for costs and 
benefits? 
Veterinarians will benefit; farmers will 
benefit but will end up spending more 
money on visits, and possibly less money on 
antibiotics. The benefits outweigh any 
potential costs. It could take decades to see 
the effects.  
Where are there gaps in the data/evidence-
base? 
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